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 At least six pharmacoepidemiologic studies have suggested that non-steroidal anti-
inflammatory drug (NSAID) use increases the risk of venous thromboembolism (VTE), however, 
biologic mechanisms for an association are unclear. Most previous studies employed prevalent 
user case control designs; none employed a new user active comparator design. Body mass 
index (BMI), often an important confounder in pharmacoepidemiologic studies, is unavailable in 
insurance claims data and its prediction is difficult. There is increasing interest in internal 
validation via linkage to electronic health records (EHR) systems to augment claims data. The 
aims of this dissertation were: 1) to evaluate incidence of VTE following new use of NSAIDs in a 
long-term cohort of U.S. women, and 2) to explore approaches to control for unmeasured 
confounding of the association of NSAID initiation and VTE by BMI with self-reported BMI 
values available for comparison. 
 We identified new use of non-aspirin NSAIDs and incident VTE among 39,876 
participants of the Women's Health Study followed from 1993-2012 with annual questionnaires. 
We designed as-treated analyses comparing NSAIDs initiation with non-initiation and 
acetaminophen initiation comparators to estimate the relative and absolute effect of NSAID 
initiation on incidence of VTE. Propensity scores incorporating age, BMI, calendar time, and 
relevant medical, behavioral, and socioeconomic variables comorbidities updated over time 
were implemented via weighting to control for confounding. We created subsamples to mimic a 
claims data analysis (without BMI data) augmented by EHR linkage and compared the 
 iv 
performance of multiple imputation (MI) of BMI under completely at random, at random, and not 
at random internal validation scenarios. 
 Initiation of NSAIDs was associated with increased VTE risk compared to non-initiation, 
but the association was null or diminished when compared with initiation of acetaminophen, an 
active comparator with similar indications but no known thrombotic effects. With internal 
validation for unmeasured BMI, MI approaches showed potential for confounding control in most 
situations despite poor prediction (R2=0.16) but with reduced effectiveness in analyses with 
small validation samples and/or few VTE events. The new user active comparator design 
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CHAPTER 1. STATEMENT OF SPECIFIC AIMS 
 
 Several pharmacoepidemiologic studies have suggested that non-steroidal anti-
inflammatory drug (NSAID) use increases the risk of venous thromboembolism (VTE), however, 
biologic mechanisms for a causal association are unclear. Body mass index (BMI), an important 
confounder in the association of NSAID use and VTE, is unavailable in insurance claims data 
and its accurate prediction is difficult. There is increasing interest in internal validation via 
linkage to electronic health records (EHR) systems to augment claims data. The aims of this 
dissertation were to evaluate incidence of VTE following new use of NSAIDs in a long-term 
cohort of U.S. women, and to describe confounding of the association of NSAID use and VTE 
by BMI and explore approaches to control for unmeasured confounding in the context of a 
claims data analyses with BMI data available from an internal EHR validation study.  
1.1. Aim 1  
 Specific Aim: To estimate and compare incidence of VTE in women who participated in 
the Women’s Health Study (WHS) from 1993-2011 according to initiation of NSAID use 
compared with non-initiation of NSAIDs and initiation of acetaminophen, an active comparator 
with similar indication but without a known or believed association with thrombosis. 
 Hypothesis: We hypothesized that NSAID initiation would not show a strong association 
with VTE risk in a well-designed non-experimental study using a true ‘new user’ design and 
robust methods to control for confounding by indication.  
 Rationale: NSAIDs are among the most commonly used drugs worldwide, however 
important unintended gastrointestinal and cardiovascular effects have been established.1 
NSAID use compared with non-use has been associated with 1.5- to 3-fold VTE risks in multiple 
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non-experimental studies.2-8 However, a biologic explanation for a causal affect is unclear. 
Previous pharmacoepidemiologic studies of NSAID use and VTE outcomes leveraged a variety 
of population-based data sources, and most utilized case-control designs with exposure 
definitions based on prevalent use. Randomized trials of sufficient size to evaluate VTE risk 
have not been conducted, presumably owing to the low event rate.9 The strong associations of 
NSAID use with increased VTE risk seen in some non-experimental studies could plausibly be 
explained by confounding by indication or other residual confounding.  
1.2. Aim 2 
 Specific aim: To describe and compare methods for adjustment of unmeasured 
confounding of the association of NSAID initiation and VTE incidence by BMI by mimicking a 
claims data analysis augmented by EHR linkage with self-reported values from the WHS 
available for comparison.  
 Hypothesis: We hypothesized that both multiple imputation (MI) with internal validation 
data and active comparator design approaches would demonstrate reduction of unmeasured 
confounding comparing with fully controlled and BMI-naïve analyses. 
 Rationale: BMI, often an important confounder in pharmacoepidemiologic studies, is 
unavailable in insurance claims data and its accurate prediction is difficult. There is increasing 
interest in internal validation via linkage to EHR systems to augment claims data in 
pharmacoepidemiologic research.10-12 Multiple imputation13 is one viable approach in such 
situations.14 An active comparator design can improve referent group comparability without a 
requirement for additional data or statistical procedures.15,16 Associations of NSAID use with 
VTE incidence in non-experimental studies are likely to be confounded by obesity. The WHS 
provided a unique opportunity to compare approaches to adjust for unmeasured confounding in 
this scenario using ‘real’ data of a long-term cohort of women with self-reported values available 
for comparison.  
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CHAPTER 2. BACKGROUND AND REVIEW OF LITERATURE 
 
2.1. Public health significance of VTE 
 Deep vein thrombosis (DVT) is a condition where blood clots form within veins, most 
commonly in the lower extremities. Pulmonary embolism (PE) is a less common but potentially 
fatal consequence where clots formed in the venous circulation travel to the pulmonary 
circulation causing infarction of the lung. Collectively, these processes are referred to as VTE. 
Risk factors for VTE include older age, obesity, hormonal factors (pregnancy, postmenopausal 
hormone therapy, oral contraceptives), travel, previous personal or family history, genetic 
variants affecting coagulation, cancer, hospitalization, trauma, major surgery, major lower 
extremity and spinal orthopaedic procedures, spinal cord injuries, and other immobilizing 
conditions.17  
 VTE is a substantial public health problem affecting an estimated 350,000 to 600,000 
Americans and possibly contributing to 100,000 deaths annually.18 Annual incidence has been 
reported as approximately 1 per 1,000 among adult populations aged 40-60 years, increasing 
sharply with age thereafter to approximately 8 in 1,000 or more among adults over 80.19,20 The 
true incidence and impact of VTE is widely believed to be underappreciated, due to under-
diagnosis and difficulty of measuring the indirect contribution of VTE to mortality in seriously ill 
patients.18 
2.2. Non-steroidal anti-inflammatory drugs  
 NSAIDs are among the most commonly used drugs worldwide. It is estimated that 
between 10-40% of adults in developed countries use prescribed or over-the-counter NSAIDs 
on a regular basis, principally for indication of musculoskeletal pain (e.g., arthritis and other 
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conditions).1,21 Aspirin has been available pharmacologically as a pain reliever, anti-
inflammatory, and anti-pyretic for over a century.22 The discovery of indomethacin for the 
treatment of rheumatoid arthritis in 196323 was followed by the development of over 20 
additional NSAIDs of multiple chemical classes, most notably acetic acid derivatives (e.g., 
indomethacin, sulindac, meclofenamate, tolmetin, ketorolac, diclofenac), proprionic acid 
derivatives (e.g., ibuprofen, naproxen, fenoprofen, ketoprofen, oxaprozin), enolic acid 
derivatives (e.g., meloxicam, piroxicam), and COX-2 selective inhibitors (e.g., celecoxib, 
rofecoxib, valdecoxib).22 Aspirin and most proprionic acid derivatives are currently available 
without prescription.  
 NSAIDs are a diverse group of drugs which inhibit prostaglandins through inhibition of 
cyclooxygenase (COX) enzyme binding sites, thereby mediating inflammation. COX enzyme is 
now known to exist in 2 forms; COX-2 expression is more highly concentrated at the site of 
inflammation, while COX-1 expression catalyzes prostaglandins that are involved in a broader 
array of physiologic functions. COX-2 selective NSAIDs (coxibs) were developed primarily to 
mitigate gastrointestinal intolerability attributed to the COX-1 inhibitory action of the ‘traditional’ 
(non-selective and partially selective) NSAIDs, which inhibit both COX-1 and COX-2, and 
aspirin, which is COX-1 specific.24,25 Celecoxib was the first coxib to receive U.S. Food and 
Drug Administration (FDA) approval in the U.S. (12/31/1998), followed by rofecoxib 
(11/20/1999) and valdecoxib (11/16/2000); however, subsequently realized associations with 
increased cardiovascular morbidity and mortality lead to voluntary withdrawal of rofecoxib from 
the U.S. market on 9/30/2004 and withdrawal of valdecoxib by the FDA on 4/7/2005. 
2.3. Association of NSAID use with VTE risk 
Nonexperimental studies 
 Tsai, et. al. (2002)7 examined NSAID use as an exposure in a U.S. cohort study of risk 
factors for venous thromboembolism incidence using combined data of the Atherosclerosis Risk 
In Communities study (follow-up period 1987 to 1998) and Cardiovascular Health Study (1989 
 5 
to 1999). Both cohorts underwent follow-up at least annually by telephone interview and/or 
examination. The authors reported an age-, race-, and sex-adjusted hazard ratio of VTE (DVT 
or PE) of 1.44 (1.03, 2.02) for NSAID use compared to no use, however NSAID use was not 
defined in the manuscript. It was stated the association “became null after further adjustment for 
BMI and diabetes,” however fully adjusted estimates were not provided. 
 Huerta, et. al. (2007)4 reported a positive association comparing current users to never 
users in a nested case-control study using the General Practice Research Database (adjusted 
odds ratio (OR) (95% CI), 1.86 (1.65, 2.10)). Shorter duration of use (i.e., closer to the time of 
initiation) was associated with higher relative risk (0-30 days use vs. never, adjusted OR 2.82 
(2.32, 3.39)). Analyses were adjusted for age, sex, BMI, cancer, recent fractures, recent 
surgeries, and other factors.  
 Biere-Rafi, et. al. (2011)3 conducted a case-control study using claims data from the 
PHARMO record linkage system, a Dutch population-based registry. Cases were hospitalized 
patients with primary diagnosis of PE. Adjusted ORs (95% CI) for current use (prescription 
ending ≤90 days before index date) and past use (> 90 days) of NSAIDs (all types combined) 
were 2.39 (2.06, 2.77) and 1.23 (1.14, 1.34), respectively. Risk was higher with shorter duration 
of use (first prescription within 30 days of PE vs. non-use, 4.77 (3.92, 5.81)). Interestingly, the 
authors found similar associations with current use of acetaminophen and tramadol (adjusted 
OR 1.74 (1.42, 2.14) and 4.07 (2.86, 5.75), respectively), pain relievers without known 
hemostatic effects. 
 Schmidt, et. al. (2012)6 reported increased incidence of VTE associated with use of both 
non-selective NSAIDs and coxibs in a population-based case-control study of the Danish 
National Patient Registry. Adjusted incidence rate ratios (IRR) (95% CI) comparing current use 
to no use were 2.58 (2.29, 2.76) for non-selective NSAIDs and 2.19 (1.99, 2.41) for coxibs. 
Adjusted IRRs comparing new use (first prescription filled within 60 days) to no use were 4.56 
(3.85, 5.40) and 3.23 (2.69, 3.89), respectively.  
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 Bergendal, et. al. (2013)2 reported mixed results in a comparatively smaller population-
based case-control study of Swedish women (1,196 cases and 1,248 controls included in the 
fully adjusted models); however, confidence intervals for many estimates were wide and sample 
size justification was not provided. Cases were women hospitalized in Sweden for first-time DVT 
or PE; controls were age-matched women from the Swedish Population Registry. Data were 
obtained by telephone interview. The fully adjusted OR (95% CI) for current use (≤3 months 
before index date) of any vs. no NSAIDs (proprionic acid derivatives, acetic acid derivatives, 
and coxibs combined) was 0.96 (0.78, 1.18); for the separate types of NSAIDs included (any 
use vs. none) they were 0.87 (0.70, 1.08), 1.20 (0.83, 1.75), and 1.88 (0.77, 4.57), respectively. 
ORs for current use increased with increasing cumulative dose for acetic acid derivatives and 
coxibs (e.g., adjusted ORs for cumulative dose >25th and ≥75th percentile, 1.55 (0.80, 2.98) and 
2.74 (0.53, 13.96), respectively).  
 Lee, et. al. (2016)5 conducted a case-control study using EHR data from primary care 
clinics throughout the UK (The Health Improvement Network). The authors restricted the study 
population to patients with an indication for NSAIDs by requiring a diagnosis of knee 
osteoarthritis and receipt of at least one NSAID prescription. Person-time during using of more 
than one NSAID type within 60 days was also excluded from the sampling frame. The adjusted 
OR (95% CI) for current use (within <60 days) of any NSAID vs. remote use (>365 days ago) 
was 1.4 (1.3, 1.4). For recent use (60-365 days) vs. remote use was 1.4 (1.4, 1.5). Methods for 
confounding control included restriction, matching (age, sex, and calendar index date), and 
multivariable modeling (obesity, smoking, comorbidities, and health care utilization indicators).  
Experimental studies 
 Experimental studies of sufficient size to evaluate VTE incidence following treatment 
with NSAIDs have not been conducted, presumably owing to the low event rate of VTE. 
However, Goy, et. al. (2014)9 recently reported a systematic review of randomized trials from 
1980-2011 that compared rofecoxib to placebo for any indication and reported data of VTE 
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events during follow-up. From 15 studies identified for inclusion, combined VTE events among 
persons in rofecoxib vs. placebo arms were 8 of 9,217 (pooled incidence rate per 100,000 
person-yrs, 86.7 (95% CI 37.5, 171.2)) and 9 of 9,092 (99.1 (45.3, 188.0)), respectively. The 
follow-up period was 6 months or less in 8 of the 15 studies. The authors concluded that pooling 
of all available published data yielded insufficient sample size to draw conclusions.  
2.4. Biologic plausibility of a causal association 
 Notwithstanding recent epidemiologic observations, a biologic explanation for an 
association between NSAID use and VTE outcomes is not immediately clear. The association of 
coxibs with serious cardiovascular outcomes is well-documented, and a mechanism has been 
posited whereby COX-2 inhibition reduces the synthesis of prostacyclin that normally functions 
as an inhibitor of platelet activation.26,27 Opinions differ regarding whether arterial and venous 
thrombotic diseases are etiologically connected or distinct.28-31 Shared strong risk factors include 
obesity and older age; other strong cardiovascular risk factors (i.e., hypertension, diabetes, and 
smoking) are modestly associated with VTE.31 The composition of arterial and venous thrombi 
and triggers for their formation are different.32 That said, it is possible that the known biologic 
actions of COX-2 inhibition might increase the propensity for thrombosis in both the venous and 
arterial sides of the circulatory system. Observations that increased VTE risk accompanies the 
use of non-selective NSAIDs as well as coxibs corroborate this hypothesis.33 Other plausible 
explanations for the associations observed in non-experimental studies include confounding by 
indication (i.e., an inflammatory process associated with the reason for using NSAIDs could be 
a driver of increased VTE risk34) and/or other sources of unmeasured or residual confounding.  
2.5. Unmeasured confounding by BMI 
 Crude associations of NSAID use initiation to VTE incidence are likely to be confounded 
by obesity in non-experimental designs. The association of obesity with increased VTE risk is 
well established.35-37 Multiple studies have identified obesity as an important risk factor generally 
associated with an approximate 2-fold risk of VTE.7,28,29,35 Numerous plausible mechanisms for 
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the independent association of obesity to VTE have been posited including effects related to 
physical circulatory constraint, increased circulating leptin,38 increased coagulation cascade 
activity, and decreased fibrinolysis. Other conditions associated with obesity, such as diabetes, 
may also contribute to observed associations.39 The association of obesity with pain, the 
principal indication for the use of NSAIDs, is also well-established.40-42  
 Unmeasured confounding is a common challenge in non-experimental 
pharmacoepidemiologic studies. Many commonly used data sources lack measurements of 
important covariates such as obesity, smoking, and activity level. There have been important 
recent advances in analytic methods designed to adjust for unmeasured confounding using 
validation data in such situations. Single and multiple imputation are longstanding methods 
whereby estimation of the unmeasured value does not or does, respectively, require data on the 
outcome in the validation sample.43,44 Propensity score (PS) calibration has been proposed for 
external adjustment of covariates unmeasured in claims data using a cross sectional validation 
study in situations where the outcome is not available.45,46 However, the key required 
assumption of surrogacy is restrictive and cannot be evaluated in the absence of outcome data. 
Lunt, et. al. proposed a structural equation approach (‘path analysis’) to predict bias of PS 
calibration without the assumption of surrogacy.47  
 BMI, often an important confounder in pharmacoepidemiologic studies, is unavailable in 
insurance claims data and its accurate prediction is difficult.48 Claims-based case definitions and 
risk scores to identify obesity have been developed, but their suitability for use in confounding 
control is limited by poor sensitivity.49,50 There is increasing interest in internal validation via 
linkage to EHR systems to augment claims data in pharmacoepidemiologic research.10-12 MI is 
an appropriate approach in such situations.14 Another is an active comparator design, which 
compares the treatment of interest with another treatment that shares the same indication but is 
not believed to be associated with the outcome.15,16 Restriction to individuals with indication for 
treatment increases the similarity of the groups on both measured and unmeasured 
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characteristics.16 Practical benefits of an active comparator design include reduction of 
confounding by factors that are unmeasured or difficult to measure, and improvement of the 
comparison in terms of clinical relevance15,51 without a need for additional data or statistical 
procedures. Huitfeldt, et. al. argued, that under certain conditions with a suitable comparator, an 




CHAPTER 3. METHODS 
 
3.1. Data source 
 The WHS is a randomized controlled trial (RCT) designed to evaluate the possible 
benefits of low-dose aspirin and vitamin E for the primary prevention of cardiovascular disease 
and cancer in U.S. women.53-55 From 1993 to 1995, 39,876 female health professionals aged 45 
years or older were randomized to a regimen of low dose aspirin and/or Vitamin E or placebo 
groups in a 2 x 2 factorial design. The trial also initially included a beta-carotene component, 
which was discontinued after 2 years median treatment duration.56 
  Eligibility criteria for enrollment included: female; aged 45 years or older; post-
menopausal or had no intention of becoming pregnant; no prior history of coronary heart 
disease, cerebrovascular disease, or cancer (except non-melanoma skin cancer); no history of 
serious side effect to any study treatments (aspirin, Vitamin E, or beta-carotene); not taking 
aspirin, aspirin-containing medications, NSAIDs, Vitamins A or E, or beta-carotene more than 
once per week; willingness to forgo the use of non-study aspirin, aspirin-containing medications, 
and NSAIDs; not taking anticoagulants or corticosteroids; and successful completion of a 3-
month run-in phase involving placebo medication, a food frequency questionnaire, and blood 
sample collection from those who were willing to give blood samples.57,58 
 Participants were followed annually through the scheduled end of the trial (March 31, 
2004) and for post-trial observation afterward. Annual follow-up data were collected via written 
questionnaires that participants returned by mail. Incidence of DVT and PE was assessed at 
every annual questionnaire. Reported DVT and PE events underwent a process of medical 
record verification by an Endpoint Committee. Blood sample analysis for genetic risk factors for 
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VTE (factor V Leiden, the G20210A prothrombin mutation, the MTHFR 677C>T polymorphism, 
and ABO blood type) were also obtained for 26,779 (67%) of the women,59 however those data 
were not available for this study.  
3.2. Data structure 
 For each woman, each cumulative year period of annual follow up (assuming no missing 
questionnaires) corresponds roughly to an annual questionnaire. During the RCT phase of the 
study, each questionnaire was designed to be administered at times referenced from 
randomization through 120 months post-randomization (12, 24, 36, 48, 60, 72, 84, 96, 108, and 
120 months following randomization). Enrollment of the cohort took place over 3 years (1993 to 
1995); however, the cessation of the RCT phase of the study occurred on a single calendar date 
before all women had reached the 120-month questionnaire. At that time, the Health History 
form was administered to all women simultaneously as a final survey instrument for the RCT, 
and women were asked to voluntarily participate in a continuing post-trial observational follow-
up phase. Approximately 6 months after administration of the Health History form, the Risk 
Factor form was administered to the subset of 90% who elected to continue, and annual 
surveys for the observational follow-up phase were administered in unison thereafter. 
Questionnaires from pre-randomization through the 7th year post-RCT were available for our 
study. Post-trial observational follow-up questionnaires 1, 2, 3, 4, 5, 6, and 7 correspond, 
respectively, with calendar years 2005 through 2011.  
 An analysis dataset for our study was provided by the Division of Preventive Medicine, 
Brigham and Women’s Hospital. Variables relevant to the study of NSAIDs and VTE outcomes 
were included for all time points at which data were collected. The completion date of each 
questionnaire was also provided. Medication use including NSAIDs and acetaminophen was 
asked each year in terms of number of days used in the past month (i.e., prevalent use). 
Illnesses, new diagnoses, or procedures reported on questionnaires were accompanied by the 
confirmed or participant-reported date for the event. Events that represented primary and 
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secondary endpoints of the study underwent a process of confirmation by an Endpoint 
Committee; these include malignant cancers (colon, lung, breast, melanoma, non-melanoma 
skin, other), myocardial infarction, stroke, coronary artery bypass graft, percutaneous 
transluminal coronary angiogram, DVT, and PE. All deaths were verified, and causes 
determined by a Death/Endpoint Committee. Certain other reported outcomes were confirmed 
with the participant by follow-up questionnaire (e.g., diabetes, gastrointestinal bleeding, ulcers).  
 Incident diagnoses were also sometimes assigned by endpoint reviewers when other 
reported events are disconfirmed (e.g., self-reported myocardial infarction is frequently 
disconfirmed to diagnosis of angina55). Unreported study endpoints could also be identified and 
confirmed in the process of Endpoint Committee reviews, or reviews of other correspondence. 
Thus, diagnoses or procedures could be entered into the study database in the absence of a 
self-report. Some illnesses, new diagnoses, and procedures that are etiologically related were 
collapsed into relevant composite outcomes for the purposes of this study.  
3.3. Exposures  
 NSAID and acetaminophen use was assessed upon enrollment and at each annual 
questionnaire for the duration of the study except the 6th post-trial observational follow-up 
questionnaire. The ascertainment of self-reported NSAID use from WHS questionnaires is 
described in detail in Chapter 4 (see Table 4.7). The exposure of interest was NSAID 
medications exclusive of aspirin. Aspirin has distinct anti-platelet properties believed to reduce 
VTE risk in some settings, and is sometimes administered for secondary prevention of VTE in 
high-risk patients.60,61 Traditional NSAIDs and coxibs, on the other hand, may be associated 
with increased risk of VTE.4,6 Enrollment into the WHS required lack of regular use of NSAID’s, 
aspirin, and aspirin-containing medication as an inclusion criteria for entry into the study 
(defined on the questionnaire as “no more than one day per week, on average” for each 
medication) in addition to an agreement of willingness to forgo use of these medication during 
the study.  
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 Each annual follow-up questionnaire (except observational follow-up 6) asked the 
participant how many days she used NSAIDs and acetaminophen in the past month, with 
answers classified as none, 1-3 days, 4-10 days, 11-20 days, or 21+ days. We defined ‘regular 
use’ as ≥ 4 days/month (at least once per week on average) because this corresponded most 
closely to the WHS inclusion criteria for non-use of NSAIDS. Lack of regular use was defined as 
0 or 1-3 days use per month. Beginning with the 84-month post-randomization questionnaire, 
the NSAID use query was separated into 2 questions, one for ‘COX-2 Inhibitors (e.g., Celebrex, 
Vioxx)’ and one for ‘other non-steroidal anti-inflammatory agents (e.g., Motrin, Advil, Aleve)’, 
which we refer to herein as traditional NSAIDs.  
 The primary treatment of interest was initiation of any NSAID, which we defined as the 
self-reported regular use of either traditional NSAIDs or coxibs. Traditional NSAIDs and coxibs 
were also analyzed separately because there are theoretical and epidemiologic bases to expect 
different associations with VTE. At study entry, all women were considered non-users of 
NSAIDs according to the study inclusion criteria; therefore, all women were classified as eligible 
to initiate NSAIDs on their first questionnaire after randomization. Acetaminophen non-use was 
not required for study entry; therefore, we required a washout period to become eligible. Women 
who stopped using after initiating could become eligible to initiate again after a washout period. 
Further descriptions of exposure ascertainment and construction of the new user cohorts are 
provided in Chapter 4.   
3.4. Outcomes 
 On each questionnaire women were asked if they had been newly diagnosed with DVT 
or PE since they last returned a questionnaire. Reported events underwent a process of 
verification by medical records with informed consent of participants. DVT was confirmed by a 
positive venous ultrasonogram or venography report. PE was confirmed by a positive 
angiogram or computed tomography scan of the chest, or a ventilation–perfusion scan with 2 or 
more mismatched defects. Deaths due to pulmonary embolism were confirmed according to 
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autopsy reports, symptoms, circumstances of death, and medical history, as judged by Endpoint 
Committee adjudicators. VTE outcomes were classified as DVT or PE (whichever occurred 
first), or as ‘both’ if confirmed DVT and PE occurred within 3 days of each other.12,22,29  
 The VTE were further classified by the endpoint reviewer as provoked and unprovoked 
according to the proximity of the event to high-risk conditions (malignancy, trauma, or major 
surgery) using previously established definitions.59,62 Unprovoked VTE was defined as those 
occurring in the absence of a known malignant condition (diagnosed either before or within 3 
months after the VTE), or trauma or surgery, within 3 months before the VTE. Provoked VTE 
was defined as those occurring in the presence of cancer, during or within 3 months of trauma 
or surgery. The dataset included a confirmed date of diagnosis for VTE events. Our outcome of 
interest was first VTE during WHS participation. We did not analyze repeated VTE events for 
this study, however we included women (2.9%) with a history of VTE before randomization.  
3.5. Covariates 
 Data for relevant covariates were provided for baseline and all follow-up questionnaires 
from which they were collected. The WHS collected a rich set of covariates with updated values 
collected periodically over time at intervals that varied according to the particular covariate. 
Covariates of interest for the current study included those desired for descriptive purposes as 
well as for estimation of PSs. Table 3.1 lists covariates available in the analysis dataset. For 
incident events, diagnoses, and procedures, participants were typically queried regarding 
whether they had received each as a new diagnosis or new procedure since their last 
questionnaire. The initial WHS survey also asked for previous history of these conditions before 
study entry. For each condition, the Division of Preventive Medicine provided a baseline history 
indicator (yes or no) and the date of first incidence during WHS follow-up. Therefore, we had 
information to construct a time-varying indicator to represent whether or not the woman had yet 
experienced a first lifetime incidence.63 Prevalent regular use of concurrent medications of 
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interest (e.g., statins, antihypertensives, antidiabetics, etc.) was also asked cross-sectionally on 
the questionnaires (i.e., ‘Are you currently taking statins regularly?’).  
3.6. Study design 
 The proposed study is a comparative evaluation to estimate and compare incidence of 
venous thromboembolism in women who participated in the WHS according to initiation of 
NSAID use, and to explore approaches for adjustment of unmeasured confounding in the 
setting of a claims data analysis with internal EHR validation data. To achieve these aims, we 
used the longitudinal data the WHS participants to construct cohorts of women who initiated 
NSAIDs and comparator cohorts of women who did not initiate or who initiated acetaminophen. 
 Current use and new use (initiation) of NSAIDs were identified using data from baseline 
and sequential yearly follow-up questionnaires of the study participants as described in earlier 
sections of this chapter, and in additional detail in Chapter 4. Briefly, each time each woman 
was eligible to initiate or not initiate, the exposure status for that questionnaire was declared and 
covariate values for that observation were determined (Figure 3.1). In order to ensure that 
covariate values preceded exposure, lagged values that were current at the time of the most 
recent previous questionnaire were used to predict initiation or non-initiation. The unit of 
analysis was the questionnaire, and women could contribute more than one questionnaire to the 
study. Each questionnaire also had its own uniquely defined at-risk follow-up period which 
began on the questionnaire date. This design was introduced by Hernan, et. al. (2009),64 and 
described subsequently in the context of time-to-event analysis by the CASCADE collaboration 
writing group (Jonsson-Funk, corresponding author).65 
 We designed as treated (AT) and initial treatment (IT) analyses with at-risk periods 
beginning on the questionnaire date (index date) (Figures 3.2, 3.3, 3.4). The at-risk follow-up 
period for VTE was constructed separately for each questionnaire, and the same inter-
questionnaire period(s) of an individual woman’s calendar time could be contained in the at-risk 
follow-up periods of more than one eligible questionnaire.64,65 For AT design, the at-risk follow-
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up time was censored on the earliest of the first reported treatment change (stopping, or 
switching to or adding a different non-aspirin NSAID), the first reported regular use of the active 
comparator, or death, withdrawal, or end of study follow-up. For IT design, treatment changes, 
starting, stopping, adding, and/or switching of therapy were ignored. The at-risk follow-up time 
of each questionnaire was furthermore limited to 5 yrs following initiation or non-initiation for 
both designs. We conducted sensitivity analyses to explore variations on our censoring 
decisions. We did not consider beginning the at-risk period earlier than the questionnaire index 
date because it would introduce immortal time bias.66 Because we only evaluated first incident 
VTE during WHS participation, a woman who experienced a VTE endpoint was ineligible to 
contribute initiation or non-initiation questionnaires after the VTE date (i.e., she was no longer at 
risk for a first VTE).  
3.7. Analytic methods 
 We used Cox proportional hazard models to estimate hazard ratios using time from 
initiation to first confirmed VTE event or censor as the dependent variable. We used a robust 
variance to account for repeated observations of the same participant.67 We estimated PSs 
using logistic regression and constructed weights from the PS to standardize the comparator 
group to the treatment group on all covariates to control confounding.68 Covariates for the PS 
were selected on the basis of substantive knowledge with the goal of capturing important 
confounders and known risk factors for VTE.69 NSAID utilization is known to have changed 
during the time period of the study in relation to the introduction and subsequent withdrawal of 
COX-2 specific NSAIDs.1 Therefore, we incorporated interaction by calendar time into the PS by 
using separate models for 2-year calendar time periods.70  
 For the Aim 2 objectives, a simplified PS was identified that incorporated interaction with 
3 clinically relevant eras of calendar time for scenarios where questionnaires across the era of 
time were included in the analysis model. For our scenarios of cross-sectional linkage (e.g., the 
internal validation samples were matched to baseline BMI values), there were no data from later 
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periods with which to model calendar time trends in the imputation model. In those situations, 
the relationships of secular time expressed in the analysis model could not be preserved in the 
imputation model.  
3.8. Characteristics of the WHS cohort 
 The WHS enrolled 39,876 women aged ≥45 yrs between 1993-1995. 39,786 participants 
who completed at least one follow-up questionnaire containing NSAIDs use data were 
potentially eligible for inclusion in our analysis (90 women from the overall cohort did not meet 
this criteria). Of those, 29,527 (74%) reported using NSAIDs regularly at some time during the 
study. The prevalence of self-reported regular use of NSAIDs on each distinct questionnaire is 
shown on Figure 3.5. Despite women’s agreement to forgo use of NSAIDs during the WHS trial, 
10% reported using NSAIDs regularly 12 months after randomization.  
 Dramatic secular trends of NSAID utilization were evident in association with the 
introduction of coxibs in late 1999 and subsequent withdrawal of some coxibs beginning 2004 
(Figure 3.5, 3.6). Decreased prevalent and new use of traditional NSAIDs coincided with the 
introduction of coxibs, after which sharp decreases of prevalent and new use of coxibs coupled 
with sharply increased traditional NSAID use characterized the time of coxib withdrawal. These 
trends underscore the importance of incorporating interaction with calendar time in our PS 
models.  
 Confirmed incident VTE was observed in 949 women (Table 3.2), corresponding with an 
overall 17-year unconditional VTE risk of 0.024. Glynn, et. al. (2007) reported the ten-year 
conditional risk of VTE for the duration of the WHS RCT as 0.012 (482 confirmed events at 
conclusion of the RCT with 10 years follow-up).59 Crude annual incidence of VTE in the WHS 
increased over time from 0.8 to 2.0 per 1,000 person-yrs from 1994-2009 (Figure 3.7). The 
prevalence of obesity (defined as BMI >= 30 kg/m) at study baseline was 18%. Qualitatively, the 
unconditional risks of VTE and regular NSAID use sometime during WHS follow-up was 
increased among those with greater BMI (Table 3.3).  
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3.9. Tables and Figures 
 
Table 3.1. Variables available in the WHS analytic dataset 
Participant characteristics 
Age 









Smoking (current, former, never)30 
Alcohol consumption 
Physical exercise – time in physical/recreational activities (met-hours per week)71 
Hormonal factors 
Menopausal status (pre, post, uncertain) 
Use of hormone replacement therapy 
Use of oral contraceptives 











Raloxifene (US approved in the mid-2000’s) 
Vitamin supplement use 
Multivitamins  
Vitamin B supplements72,73 
Non-study Vitamin E 
Medical conditions / events1  
Composite outcomes: 
Coronary heart disease (confirmed myocardial infarction, angina, coronary 
artery bypass graft, coronary angioplasty) 
Cardiopulmonary (congestive heart failure, chronic lung disease) 
Cerebrovascular disease or events (congestive heart failure, chronic lung 
disease) 
Cancer (colon, lung, breast, melanoma, ‘other’)74-76 
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Gastrointestinal (gastrointestinal bleeding, peptic ulcer disease) 
Major orthopaedic event (fractures, total joint replacement)  
Diagnoses 
Elevated cholesterol (diagnosed by physician) 
Diabetes (diagnosed by physician)7,28  





Osteoarthritis; joint pain or swelling  
Osteoporosis 
VTE history 
Personal history of DVT or PE before enrollment78 (assessed on run-in questionnaire) 
Family history of DVT (collected on 4th post-trial observational follow-up questionnaire) 
 
1Baseline history indicator, plus date of first incident event during follow-up for those without 
history prior to enrollment 
Abbreviations: WHS= Women’s Health Study, BMI= body mass index, VTE= venous 




Table 3.2. Joint distributions of event type and provocation status of confirmed VTE 
among 39,786 WHS participants that completed at least one follow-up questionnaire 
 
  
Type of event Total No Yes
Could not 
determine
   Any type (PE, DVT, or both)
2
949 381 546 20
   PE with or without DVT 406 167 234 5
   DVT only 543 214 312 15
Table 4. Joint distributions of event type and provocation status of confirmed VTE among 39,786 WHS 
participants that completed at least one follow-up questionnaire
VTE coincided with a provocating factor
1
1
Provocating factors were cancer diagnosed previously or within 3 months after the VTE event, or trauma 
or surgery within 3 months prior to the VTE event
2
Occurrence of DVT and PE together was defined as diagnoses confirmed within +/- 3 days of one another
Abbreviations: VTE= venous thromboembolism, WHS= Women's Health Study, PE= pulmonary embolism, 
DVT= deep vein thrombosis
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Table 3.3. Bivariate distributions of baseline BMI by self-reported use of an NSAID 4+ 
days/mo and confirmed VTE event anytime during WHS observation 
 
   
Total < 25 25 -30 >30
Reported NSAID use 4+ days/mo anytime during WHS observation
Number 29,527 14,259 9,368 5,873
Total number
1
39,786 20,120 12,323 7,288
Proportion 0.74 0.71 0.76 0.81
VTE event during WHS observation
Number of of women with an event 949 352 343 251
Total number 39,786 20,120 12,323 7,288
Proportion 0.024 0.017 0.028 0.034




Excludes 90 WHS enrollees with no follow-up questionnaires
Abbreviations: BMI= body mass index, NSAID= non-steroidal anti-inflammatory drugs, VTE= venous 
thromboembolism, WHS= Women's Health Study
Table 4. Bivariate distributions of baseline BMI to occurrence of VTE or NSAIDs initiation at some 
time during follow-up among 39,786, Women's Health Study, 1993-2011.
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Figure 3.1. Schematic diagram illustrating the classification of eligibility, initiation or non-
initiation, and treatment change for a hypothetical questionnaire with as treated design  
Covariate values that were up-to-date at the beginning of the initiation eligibility period were 































Figure 3.2. Schematic diagram illustrating sequential observations for a hypothetical 
woman with initial treatment (first treatment carried forward) design 
with follow-up extended indefinitely until the earliest of a VTE event, administrative censor, 
death, or withdrawal from the study. Numbers 1-14 represent sequential yearly questionnaires. 
This woman would contribute 7 observations to an unrestricted IT analysis, according to her 
pattern of self-reported prevalent use of NSAIDS at each time point. Under an unrestricted IT 
design, she would be classified as exposed on the 7th questionnaire and unexposed on the 1st 
through 6th questionnaires and would experience the outcome for all 7 with the appropriate time-
to-event calculated for each. 
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Figure 3.3. Schematic illustration of the same hypothetical woman with initial treatment 
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Figure 3.4. Schematic diagram illustrating sequential questionnaires for a hypothetical 
woman with as treated design created by censoring  
The at risk follow-up time of each questionnaire was censored at the earliest of treatment 
change, a VTE event, administrative censor, death, withdrawal from the study, or 5 years 
following initiation or non-initiation. This woman would contribute one exposed questionnaire 
culminating in VTE, and 6 unexposed questionnaires censored without VTE. 
 
  




















Figure 3.5. Prevalent self-reported use of traditional NSAIDs and coxibs on sequential 
questionnaires among all WHS participants 









































Figure 3.6. Annual incidence rates of initiation of traditional NSAIDs and coxibs during 
1994-2010  


















































































Yearly incidence rates of venous thromboembolism, 1993-2010
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CHAPTER 4. INCIDENCE OF VENOUS THROMBOEMBOLISM FOLLOWING INITIATION 
OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN U.S. WOMEN 
 
4.1. Introduction 
 Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used 
drugs worldwide. Approximately10-40% of adults in developed countries are prescribed or use 
over-the-counter NSAIDs on a regular basis, principally for musculoskeletal pain.1,79 Venous 
thromboembolism (VTE) is a substantial public health problem affecting an estimated 350,000 
to 600,000 Americans and possibly contributing to 100,000 deaths annually.18 Approximately 1 
of 1,000 adults aged 40-60 years and 8 of 1,000 adults over 80 years are affected.19,20  
 NSAID use compared with non-use is associated with 1.5- to 3-fold VTE risks in multiple 
non-experimental studies.2-8 However, a biologic explanation for a causal effect is unclear. 
NSAIDs inhibit prostaglandins through inhibition of cyclooxygenase (COX) enzyme binding 
sites, thereby reducing inflammation. The association of COX-2 selective inhibitors (‘coxibs’) to 
serious arterial cardiovascular outcomes is well established, and a mechanism has been 
posited whereby COX-2 inhibition reduces the synthesis of prostacyclin that normally functions 
as an inhibitor of platelet activation.26,27  
 Opinions differ regarding whether arterial and venous thrombotic diseases are 
etiologically connected or distinct.28-31 Shared strong risk factors include obesity and older age; 
other strong cardiovascular risk factors (i.e., hypertension, diabetes, and smoking) are modestly 
associated with VTE.31 The composition of arterial and venous thrombi and triggers for their 
formation differ.32 It is possible that biologic actions of COX inhibition could increase the 
propensity for both venous and arterial thrombosis,80 however, the associations seen in non-
experimental studies could also be explained by confounding by indication.  
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 Randomized trials of sufficient size to evaluate VTE risk have not been conducted, 
presumably owing to the low event rate.9 At the same time, the limited scope of treatment 
options for individuals with chronic pain81 coupled with national calls for improved prevention of 
VTE18 underscore the importance of defining the risk of VTE associated with NSAIDs. We 
therefore undertook this study to evaluate the risk of VTE following new use of NSAIDs in a 
long-term cohort of U.S. women.  
4.2. Methods 
Data source 
 The Women’s Health Study (WHS) is a double-blind randomized controlled trial of low-
dose aspirin, vitamin E, and beta-carotene for the primary prevention of cardiovascular disease 
and cancer in U.S. women.53-55 From 1993 to 1995, 39,876 female health professionals aged ≥ 
45 yrs were allocated to a regimen of aspirin (100mg every other day) or placebo and Vitamin E 
(600 IU every other day) or placebo in a 2 x 2 factorial design. The trial also initially included a 
beta-carotene component, which was discontinued after 2 years median treatment duration.56 
 Eligibility criteria for enrollment included: female; aged 45 years or older; post-
menopausal or had no intention of becoming pregnant; no prior history of coronary heart 
disease, cerebrovascular disease, or cancer (except non-melanoma skin cancer); not taking 
aspirin, aspirin-containing medications, NSAIDs, Vitamins A or E, or beta-carotene more than 
once per week; willingness to forgo the use of non-study aspirin, aspirin-containing medications, 
and NSAIDs; not taking anticoagulants or corticosteroids; and successful completion of a 3-
month placebo run-in.58  
 Participants were followed annually through the scheduled end of the trial (March 31, 
2004) and for post-trial observation afterward. Data were collected via written questionnaires 
that participants returned by mail. Complete descriptions are available elsewhere.57,58 The 
current study includes questionnaires of all WHS participants through 7 years post-trial.  
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NSAID use 
 Questions regarding current use of non-aspirin NSAIDs were included in 19 of 20 
questionnaires administered during the study period: before randomization (baseline); every 12 
months through 120 months following randomization; at trial conclusion in 2004; and 1, 2, 3, 4, 
5, and 7 years after trial conclusion for participants (~90%) of the observational follow-up phase. 
We classified self-reported use of ‘traditional’ NSAIDs (i.e., non-aspirin non-COX selective 
NSAIDs), coxibs (COX-2 inhibitors), and any NSAID (not including aspirin) from WHS 
questionnaire responses. Details are provided on Table 4.1. We defined regular use as 4 or 
more days self-reported use in the past month, which corresponded most closely with the WHS 
entry criteria.  
VTE outcomes 
 Each year women were asked whether they had been newly diagnosed with deep vein 
thrombosis (DVT) or pulmonary embolism (PE) since their last questionnaire. As VTE was a 
secondary trial endpoint, reported events underwent medical records verification by an Endpoint 
Committee of physician reviewers with consent of the participant. Events discovered during 
medical record reviews for other study endpoints were also captured. DVT was confirmed based 
on a positive venous ultrasonogram or venography report. PE was confirmed based on a 
positive angiogram or computed tomography scan of the chest, or a ventilation–perfusion scan 
with 2 or more mismatched defects. Deaths due to pulmonary embolism were confirmed 
according to autopsy reports, symptoms, circumstances of death, and medical history, as 
judged by Endpoint Committee adjudicators.  
 VTE events were also classified by the endpoint reviewer as DVT, PE, or both if 
confirmed DVT and PE occurred within 3 days of each other, and as provoked (cancer 
diagnosed before or within 3 months after the VTE, or trauma or surgery within 3 months before 
the VTE) or unprovoked (absence of same).59,62 Date of diagnosis for the first confirmed incident 
event during WHS follow-up was utilized for the current analysis. Subsequent VTE events were 
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not evaluated for this study, however women with self-reported history of VTE at study entry 
(2.9% of WHS participants) were included in the analysis.  
Covariates 
 Covariates were ascertained before randomization and were updated whenever 
possible. Race, education, and history of VTE before study enrollment were collected once at 
baseline. Age was calculated at every questionnaire. Body mass index (BMI), smoking (current, 
previous but not current, or never), physical exercise, alcohol use, multivitamin use, 
menopausal status (pre-menopausal, post-menopausal, or uncertain), and hormone 
replacement therapy use (current, previous but not current, never) were reassessed only on 
some questionnaires. The last recorded values were carried forward to later questionnaires 
where they were not asked for or missing unless described otherwise. Missing values were not 
imputed with later values with the exception of baseline height, which was imputed with values 
from later questionnaires if available.  
 BMI was calculated from self-reported height and weight and carried forward by linear 
interpolation. Self-reported weight was highly correlated with measured weight (r=0.97) among 
similar women in the Nurses’ Health Study.82 Menopausal status was imputed to post-
menopausal for all women at ages ≥ 60 years in the absence of self-report data indicating 
otherwise.83 Physical exercise was classified as 0, 0<-<3.75, 3.75-< 7.5, 7.5-<15, 15-<22.5, and 
22.5+ met-hours per week;71,84 7.5 met-hours represents the minimum physical activity for 
adults recommended by Federal guidelines.85  
 Women were questioned yearly regarding new diagnoses of cancer, cardiovascular 
disease events, and other conditions, and use of selected medications. As cancer and incident 
cardiovascular disease were primary trial endpoints, occurrences including heart failure during 
follow-up underwent medical record verification by an endpoint committee of physician 
reviewers with consent of the participant.53,55,86 Self-reported incident diabetes was verified via a 
physician-conducted telephone interview or validated self-administered questionnaire that 
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inquired about symptoms, diagnostic testing, and use of diabetic medications.87 Self-reported 
peptic ulcer disease (PUD) and gastrointestinal (GI) bleeding were verified with a follow-up 
questionnaire. We used confirmed incident diagnoses for these covariates, except that self-
reported PUD and GI bleeding diagnoses were accepted after 2005 because follow-up 
verification for those endpoints was discontinued after trial completion.  
 Hypertension was defined as a self-reported diagnosis, self-reported use of 
antihypertensive medication, or self-reported systolic blood pressure ≥140 mmHg or diastolic 
≥90 mmHg. Atrial fibrillation, osteoarthritis, rheumatoid arthritis,77,88 osteoporosis, major 
orthopaedic event (fracture or joint replacement), migraine headaches, chronic lung disease, 
and coagulation disorder diagnoses were self-reported. Dates of first lifetime incidence, whether 
before enrollment or during follow-up, were identified for all diagnoses and events of interest. 
Self-reported concurrent regular use ( 4 days in the past month) of acetaminophen, non-study 
aspirin, and aspirin containing medications was asked each year, and statins on 13 
questionnaires.  
Study design 
 The primary exposure and outcome of interest were initiation of any NSAID and time to 
first confirmed VTE. We constructed a new user design that treated the questionnaire as the 
unit of analysis.64,89 Using each woman’s sequential questionnaires, we defined initiation as the 
first report of regular use (4 days in the past month) following study entry, or a washout period 
of 2 or more consecutive reports of non-regular use of any non-aspirin NSAID spanning at least 
18 months from the first to last consecutive non-regular use report. That is, a report of no 
regular NSAID use on a woman’s first questionnaire following either study entry or a washout 
was classified as a non-initiation, and a report of regular use was classified as an initiation. 
Following an eligible non-initiation, the woman’s next questionnaire became eligible to initiate or 
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not initiate, and so on. Following initiation, the woman’s next and subsequent questionnaires 
became ineligible until the washout criteria was again met.  
 Each woman’s follow-up time was thereby conceptualized as a sequence of discrete 
observations, with individual women potentially contributing both non-initiations and initiations to 
the analysis over the duration of her study participation. The up-to-date covariate values on first 
day of the inter-questionnaire period preceding the questionnaire date (the “eligibility period”) 
were used as the predictors of initiation or non-initiation for each questionnaire.  
 We designed as treated (AT) and initial treatment (IT) analyses with at-risk periods 
beginning on the questionnaire date (index date). The at-risk follow-up period for VTE was 
constructed separately for each questionnaire, and the same inter-questionnaire period(s) of an 
individual woman’s calendar time could be contained in the at-risk follow-up period of more than 
one eligible questionnaire.64,65 For AT design, the at-risk follow-up time was censored on the 
earliest of: 1. the first reported treatment change (stopping, or switching to or adding a different 
non-aspirin NSAID); 2. the first reported regular use of the active comparator; or 3. death, 
withdrawal, or end of study follow-up. For IT design, treatment changes, starting, stopping, 
adding, and/or switching of therapy was ignored. The at-risk follow-up time of each 
questionnaire was furthermore limited to 5 yrs following initiation or non-initiation for both 
designs.  
 Missing NSAID use values occurring during a washout or at-risk follow-up period were 
carried forward from the last non-missing observation for the purpose of establishing the 
duration of continued use or non-use; however, we required non-missing responses for all 
variables used to define the beginning and end of washout, eligibility, and at-risk periods, 
including variables needed to define non-use of an active comparator or other concurrent 
medications required for eligibility.  
 We excluded as ineligible all questionnaires with confirmed VTE before the 
questionnaire index date, as the woman was no longer at risk for first incident VTE; this entailed 
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the exclusion of 421 otherwise eligible questionnaires (53 initiations, 368 non-initiations) for 
which VTE occurred during the initiation eligibility period. We did not consider beginning the at-
risk period earlier than the questionnaire index date because it would introduce immortal time 
bias.66  
 Coxibs were commercially available in the U.S. for approximately 1.3 yrs before WHS 
questionnaires began capturing coxib use with a separate question (Table 4.1). For all 
questionnaires without the coxib question (72 mo post-randomization and earlier), we 
considered the value of coxib use as non-use if returned on or before 12/31/1998 (date 
celecoxib released in the U.S.), and missing if returned after 12/31/1998; those classified as 
missing were excluded as ineligible to initiate or not initiate as their exposure data were 
incomplete. 324,124 eligible questionnaires of 38,493 women were included (Figure 4.1). 
 We compared initiation of any NSAID, traditional NSAIDs (exclusive of coxibs), and 
coxibs (exclusive of traditional NSAIDs) with non-initiation of any NSAID. We also compared 
initiation of traditional NSAIDs and coxibs with non-initiation by frequency of use at the time of 
initiation (4-20 days and 21+ days in the past month). We compared initiation of coxibs with 
initiation of traditional NSAIDs, and initiation of each NSAID type to initiation of acetaminophen, 
an active comparator with similar indications and without known hemostatic effects. 
Acetaminophen use was asked in the same manner as NSAIDs on each questionnaire, and we 
used the same criteria to classify current regular use (4 days in the past month). For the 
acetaminophen comparator analyses, we required nonuse of any non-aspirin NSAID and 
acetaminophen during the washout period. We did not restrict according to concurrent aspirin 
use for any analyses.  
Analytic methods 
 We used a propensity score (PS) to control for confounding. The PS incorporated all 
covariates shown in Table 4.2, with values updated over time. Variables for the PS were 
selected on the basis of substantive knowledge and causal diagram analysis with the goal of 
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including important confounders and preserving causal pathways.90 Randomized low dose 
aspirin was not associated with VTE risk in the WHS population,59 but moderate dose aspirin is 
employed as a VTE preventive in some post-surgical and other high-risk settings;61,91 therefore, 
we included non-study aspirin in the PS. We omitted concurrent acetaminophen use from the 
PS for the acetaminophen active comparator analyses.  
 The PS was estimated using separate logistic regression models for 2-calendar year 
periods.70 We used the PS to construct weights to standardize the comparator group to the 
treatment group, known as standardized morbidity ratio (SMR) weighting.68 We multiplied SMR 
weights by the marginal odds of treatment received, which redistributed their values around a 
mean of 1.92 This stabilization provided scale by which to interpret the magnitude of the weights. 
 We used SMR weighted Cox proportional hazard models to estimate the relative and 
absolute effects of NSAID initiation on time to and cumulative incidence of VTE.93 A robust 
variance was used to account for multiple questionnaires from the same woman in either or both 
treatment groups.94,95 Risks for 2 years of treatment, risk differences (RD), and number needed 
to treat for harm (NNTH) or benefit (NNTB) to one additional woman were calculated from the 
adjusted survival curves.96 Risks were multiplied by 100 to express as percentages. Confidence 
intervals for the RD and NNTH/NNTB were obtained by bootstrap with 1,000 resamples with 
replacement. The weighted copy method was employed for the PS models to facilitate the 
bootstrap.97 We plotted weighted Kaplan-Meier curves to illustrate the standardized cumulative 
incidence of VTE.98 The proportional hazard assumption for each model was assessed using 
graphical methods and Schoenfeld residual tests. SAS 9.4 software (SAS Institute, Cary, NC) 
was used for all analyses. 
Sensitivity analyses  
 We repeated our main analyses using 2-yrs, 3-yrs, and no restriction on maximum at-
risk follow-up time, with restriction to women (97%) without previous history of VTE before study 
entry, and with restriction to questionnaires with eligibility period lengths < 27 mo (99%). A 27 
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mo eligibility period limit would restrict to no more than one missing yearly questionnaire during 
the period, allowing a 3 mo grace period for late returns.  
4.3. Results 
 While all 39,876 WHS participants were non-regular users of NSAIDs at study entry by 
design, 10% reported using NSAIDs regularly 12 months after study enrollment, and 31% in 
2011. 29,527 women (74%) reported regular use of an NSAID at some time during their study 
follow-up; 71% used traditional NSAIDs and 24% used coxibs at some time. Nine hundred fifty-
one WHS participants had confirmed VTE during follow-up of which 382 (40%) were classified 
as unprovoked. The first confirmed event was PE for 408 (with accompanying DVT in 61%), and 
DVT without PE for 543.  
  Compared with non-initiation, we saw modestly elevated risk of VTE after NSAID 
initiation and greater risk with coxibs than traditional NSAIDs. The 2-yr risks (%) of VTE among 
women who initiated any NSAID, traditional NSAIDs, and coxibs, respectively, were 0.36, 0.32, 
and 0.64 in the AT analysis; among non-initiators, these risks standardized to the initiators on all 
covariates were 0.25, 0.24, and 0.32, respectively (Table 4.3, Figure 4.2). The hazard ratio (HR) 
(95% CI) for VTE in the AT analysis was 1.5 (1.2, 1.8) for any NSAID, 1.3 (1.1, 1.7) for 
traditional NSAIDs, and 2.0 (1.3, 3.1) for coxibs (Table 4.4). HRs were closer to the null value 
for the IT analysis (Table 4.4). The 2-yr RDs (95% CI) for the AT analysis were 0.11 (0.03, 
0.19), 0.08 (0.00, 0.17), and 0.32 (0.02, 0.66), respectively (Table 4.3).  
In AT analyses stratified into low (1-20 days/mo) and high (21+days/mo) frequency of use at 
initiation, HRs were similar to each other and to the overall HR for both traditional NSAID and 
coxib initiation (Table 4.5) suggesting that increased risk for coxibs was not simply a function of 
their typically daily or almost daily use patterns compared with the typically less frequent use of 
traditional NSAIDs.  
 In contrast to comparisons with non-initiation, the HRs and 2-yr RDs for AT analyses 
comparing initiation of each NSAID type with acetaminophen initiation were close to or less than 
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the null value. The 2-yr risks (%) of VTE among women not using acetaminophen who initiated 
any NSAID, traditional NSAIDs, and coxibs, respectively, were 0.39, 0.36, and 0.61; among 
acetaminophen initiators, these risks standardized to the NSAID initiators on all covariates were 
0.37, 0.37, and 0.50, respectively (Table 4.6, Figure 4.3). The HR (95% CI) for VTE was 0.9 
(0.6, 1.5) for any NSAID, 0.9 (0.5, 1.5) for traditional NSAIDs, and 1.3 (0.5, 3.2) for coxibs 
(Table 4.7); 2-yr RDs (95% CI) were 0.03 (-0.46, 0.14), -0.01 (-0.55, 0.12), and 0.11 (-0.43, 
0.73) corresponding to NNTH 3,826, NNTB 10,766, and NNTH 937, respectively (Table 4.6).  
 Sample sizes were small, particularly for coxibs (8 VTE events during AT follow-up, all 
within the first 2 years). We restricted the at-risk follow-up time for coxib vs. acetaminophen 
initiation to 2 yrs for estimation of the HR because the proportional hazard assumption was not 
met after 2 yrs (Figure 4.3 D).  
 Sensitivity analyses suggested that our findings were robust to our decisions to include 
women with prior history of VTE and ignore longer eligibility period lengths for a small (<1%) 
proportion of questionnaires (Table 4.8), and to variations of maximum follow-up time restriction 
for AT analyses with the exception of coxibs vs. acetaminophen analysis (Tables 4.9, 4.10, 
4.11). For IT analyses, HRs decreased toward the null with increasing duration of maximum 
follow-up time (Table 4.9).  
4.4. Discussion 
 Our non-initiator comparator analyses showed associations similar in magnitude to some 
previous studies2,5 with stronger associations for coxibs that did not appear to be explained by 
differences in frequency of use. Coxib initiation was associated with 80% greater VTE risk than 
traditional NSAIDs in head-to-head comparison. Compared with acetaminophen initiation, 
traditional NSAIDs did not show increased risk and coxibs showed relative and absolute risk 
increases that were attenuated compared with the non-initiator analysis.  
 Six previous pharmacoepidemiologic studies of NSAIDs use and VTE have reported 
relative risks on the order of approximately 1.5-3.0 with stronger associations for coxibs (Table 
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4.12).2-8 Goy, et. al.9 conducted a pooled analysis of data from 14 trials of randomized rofecoxib 
v. placebo that reported VTE as secondary outcomes. A difference of VTE incidence was not 
detected, but small numbers of events provided very low power (8 events / 9,217 person-yrs 
compared to 9 events / 9,092 person-yrs, respectively). Biere-Rafi, et.al. reported elevated risk 
of VTE for current use of acetaminophen and tramadol compared to non-use [adjusted OR 1.7 
(95% CI 1.4, 2.1) and 4.0 (95% CI 2.8, 5.8), respectively] in a case-control study of NSAIDs and 
VTE in a Dutch population-based registry, but did not report direct comparison of NSAIDs to 
acetaminophen or tramadol use. Since these drugs have no known hemostatic effects, the 
authors suggested these findings could indicate residual confounding by underlying conditions 
that may also influence analyses of NSAID use. In our study, the HR comparing initiation of 
acetaminophen to non-initiation (both groups exclusive of NSAID use) was 1.3 (95% CI 0.9, 1.9) 
(data not shown).  
 Our study design offers several advantages in terms of confounding and other biases. 
Previous studies of NSAIDs and VTE risk have leveraged a variety of population-based data 
sources, and most utilized case-control designs with exposure definitions based on prevalent 
use (Table 4.12). We implemented a ‘new user design’ 99 in a long-term follow-up cohort of 
women initially not using NSAIDs where users were identified at the start of treatment, 
outcomes were ascertained during follow-up, and pretreatment covariates were utilized for 
appropriate confounding control as would be done in a randomized trial. An active comparator 
design moreover increases the similarity of the groups on both measured and unmeasured 
characteristics by restricting to individuals with indication for treatment.16,52 The rich WHS 
covariate set also includes lifestyle variables not captured by claims data, and VTE 
ascertainment that captures all clinically significant events including those without a 
hospitalization (e.g., sudden death).  
 Our study has limitations. While dates of confirmed VTE were known, drug use 
information was only available cross-sectionally at yearly intervals. Thus, it was not known when 
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initiation began, or whether a non-initiator may have started and stopped between 
questionnaires. Likewise, when treatment change was detected during as-treated follow-up, the 
precise date of change was unknown. When initiation or treatment change and VTE occurred 
during the same interval, the true exposure status at the time of the VTE was unclear. However, 
in this scenario it seems more plausible that regular NSAID use would stop as a consequence 
of experiencing a VTE than that initiation would occur. Our analyses assume that the use or 
non-use reported on a questionnaire continued until day of the next questionnaire. Our sample 
sizes were small for some analyses involving coxib initiation.  
 While high prevalence of NSAID use and clinical and public health significance of VTE 
underscore the importance of understanding their association, current knowledge is limited and 
inconclusive. Pragmatically, the large sample size requirement for a randomized trial of VTE 
outcomes will necessitate that further work rely heavily on observational designs.9 For the many 
sufferers with chronic pain, options are limited and effective pharmacologic treatment is not a 
luxury that can simply be done without in the interest of risk avoidance.1 An accurate 
understanding of small but potentially serious risks associated with NSAID use is needed to 
correctly weigh the risks and benefits of treatment for affected individuals.  
Conclusion 
 Using a rich data source and robust methods for confounding control, we found that risk 
of VTE associated with NSAID use among women was not high. Importantly, little risk from 
NSAID use was seen in comparisons with initiation of acetaminophen, an active comparator 
with similar treatment indication but not known to effect VTE. Apparent increased risks seen in 







4.5. Tables and Figures 
 
Table 4.1. Ascertainment of self-reported use of NSAIDs from Women’s Health Study questionnaires 
Questionnaire(s):  Format of question (discrete answer choices):  Regular use defined: 
Study enrollment "Do you currently take any of the following on a regular 
basis, i.e., more than one day per week, on average” 
(Yes/No)  
with “Nonsteroidal anti-inflammatory agents (e.g., Motrin, 
Advil, Naprosyn, Feldene, Nuprin, Mediprin)” among a list 
of medications 
Yes1 
12, 24, 36, 48, 60, and 72 months  
post-randomization 
 
"During the past month, on approximately how many 
days did you take any of the following medications?" 
(None, 1-3 days, 4-10 days, 11-20 days, or 21+ days)  
with “Nonsteroidal anti-inflammatory agents (e.g., Motrin, 
Advil, Naprosyn, Feldene, Nuprin, Mediprin)” among a list 
of medications2  
“Mediprin” was replaced with “Aleve” beginning 36 
months post-randomization 
 
 4 days3 
84, 96, 108, and 120 months post-
randomization, trial conclusion, and 
1, 2, 3, 4, 5, and 7 yrs post-trial4 
 
Identical to above, except a separate item, "Cox-2 
inhibitors (e.g., Celebrex, Vioxx)," was additionally 
included with the same response options5 
 
 4 days3  
1 ‘No’ was required for study entry. 2 Referred to hereafter as ‘traditional NSAIDs.’ 
3 We classified 4-10 days/month or more frequent usage as current regular use, as this frequency corresponded most closely with the 
study entry criteria; 0 or 1-3 days/month was classified as non-use.  
Among all WHS questionnaires with non-missing responses, 60%, 19%, 11%, 4%, and 6% reported 0, 1-3, 4-10, 11-20, and 21+ days 
use, respectively, for traditional NSAIDs and 91%, 2%, 1%, 1%, and 5% respectively for coxibs.  
4 For 84 months post-randomization and later questionnaires, we furthermore classified current use of either type (traditional NSAIDs or 
cox-2 inhibitors) as current use of any NSAID, and non-use of both types as non-use. For questionnaires 72 mo post-randomization and 
earlier, any NSAID was traditional NSAIDs only. 5 Referred to hereafter as ‘coxibs’. The first coxib was available in the US 12/31/1998. 







Table 4.2. Covariate distributions of women with eligible questionnaires at selected survey times (number (%) of women) 
     Questionnaire (administration year) 
      12 mo post-randomization (1994-96)1   1 yr post-trial (2005)2 
      Initiations   Non-initiations3  Initiations   Non-initiations3 
      Crude     Crude   Standardized  Crude     Crude   Standardized 
Number of 
women4     3,843     34,018      2,982     15,866     
Age (yrs)  <50   1,354 (35)   10,873 (32) (35)  5 (0)   8 (0) (0) 
  50-54   1,175 (31)   9,393 (28) (31)  15 (1)   52 (0) (0) 
  55-59   668 (17)   6,195 (18) (17)  1,093 (37)   4,707 (30) (34) 
  60-64   338 (9)   3,975 (12) (9)  903 (30)   4,380 (28) (31) 
  65-69   218 (6)   2,436 (7) (6)  500 (17)   3,111 (20) (18) 
  70-74   70 (2)   890 (3) (2)  281 (9)   1,954 (12) (10) 
  75-79   18 (0)   204 (1) (0)  144 (5)   1,172 (7) (6) 
  80+   2 (0)   52 (0) (0)  41 (1)   482 (3) (2) 
Race Other   189 (5)   1,746 (5) (5)  100 (3)   815 (5) (4) 
  White non-Hispanic   3,654 (95)   32,272 (95) (95)  2,882 (97)   15,051 (95) (96) 
Education LVN/LPN   583 (15)   4,665 (14) (16)  374 (13)   1,871 (12) (13) 
  RN < 4-yr   1,749 (46)   14,606 (43) (45)  1,313 (44)   6,518 (41) (44) 
  Bachelors   838 (22)   7,936 (23) (22)  757 (25)   3,833 (24) (24) 
  Graduate   673 (18)   6,811 (20) (18)  538 (18)   3,644 (23) (19) 
Body mass index 
(kg/m2) <25   1,681 (44)   17,567 (52) (43)  1,176 (39)   7,683 (48) (40) 
 25-<30   1,278 (33)   10,464 (31) (32)  1,043 (35)   5,208 (33) (35) 
  30-<35   567 (15)   4,039 (12) (16)  528 (18)   2,037 (13) (17) 
  35+   317 (8)   1,948 (6) (9)  235 (8)   938 (6) (8) 
Smoking Never smoked   1,904 (50)   17,489 (51) (48)  1,503 (50)   8,654 (55) (50) 
  Past smoker   1,385 (36)   12,206 (36) (37)  1,242 (42)   5,946 (37) (42) 
  Current smoker   554 (14)   4,323 (13) (14)   237 (8)   1,266 (8) (8) 
Exercise  






 >0 - <3.75   832 (22)   7,488 (22) (23)   605 (20)   2,874 (18) (19) 
  3.75 - <7.5   565 (15)   4,768 (14) (14)   369 (12)   1,893 (12) (12) 
  7.5 - <15.0   690 (18)   6,408 (19) (18)   577 (19)   3,028 (19) (19) 
  15.0 - <22.5   500 (13)   4,709 (14) (13)   411 (14)   2,431 (15) (15) 
  22.5+   747 (19)   6,917 (20) (19)   719 (24)   4,172 (26) (24) 
Alcohol use Rarely/Never   1,748 (45)   15,253 (45) (44)   1,173 (39)   6,743 (42) (39) 
  1-3 drinks/mo   563 (15)   4,440 (13) (14)   361 (12)   1,868 (12) (12) 
  1-6 drinks/wk   1,154 (30)   10,820 (32) (31)   1,112 (37)   5,365 (34) (37) 
  1+ drinks/day   378 (10)   3,505 (10) (10)   336 (11)   1,890 (12) (12) 
Multivitamin use None   2,314 (60)   21,229 (62) (59)   1,315 (44)   7,370 (46) (43) 
  1-20 days/mo   544 (14)   4,395 (13) (15)   228 (8)   1,212 (8) (8) 
  >20 days/mo   985 (26)   8,394 (25) (26)   1,439 (48)   7,284 (46) (49) 
Menopausal  
status Premenopausal   1,064 (28)   9,381 (28) (28)   85 (3)   321 (2) (3) 
  Uncertain/Unclear   810 (21)   6,108 (18) (21)   207 (7)   755 (5) (6) 
  Postmenopausal   1,969 (51)   18,529 (54) (51)   2,690 (90)   14,790 (93) (91) 
Hormone 
replacement 
therapy Never   1,691 (44)   17,213 (51) (44)   569 (19)   4,049 (26) (19) 
 Former   382 (10)   3,043 (9) (10)   1,411 (47)   7,482 (47) (49) 
  Current   1,770 (46)   13,762 (40) (46)   1,002 (34)   4,335 (27) (32) 
First lifetime 
incidence  
(ever vs. never): Cancer5   7 (0)   40 (0) (0)   151 (5)   972 (6) (6) 
  Cardiovascular disease6   26 (1)   151 (0) (1)   148 (5)   875 (6) (6) 
  Cardiopulmonary disease7   405 (11)   3,081 (9) (11)   503 (17)   2,295 (14) (17) 
  Atrial Fibrillation   100 (3)   753 (2) (3)   115 (4)   683 (4) (4) 
  Hypertension8   1,120 (29)   9,027 (27) (29)   1,556 (52)   8,024 (51) (53) 
  Diabetes9   137 (4)   916 (3) (3)   171 (6)   1,037 (7) (6) 
  Coagulation disorder   3 (0)   25 (0) (0)   27 (1)   168 (1) (1) 
  
Peptic ulcer disease or 
gastrointestinal bleeding   35 (1)   164 (0) (1)   255 (9)   1,569 (10) (10) 
  Migraine Headaches   281 (7)   1,597 (5) (7)   369 (12)   1,503 (9) (12) 







Rheumatoid or osteoarthritis 
concurrent diagnosis10   979 (25)   2,544 (7) (26)   227 (8)   447 (3) (9) 
  Joint replacement or fracture   73 (2)   526 (2) (2)   171 (6)   863 (5) (6) 
  Osteoporosis   103 (3)   785 (2) (3)   395 (13)   2,375 (15) (13) 
  History of PE before study   29 (1)   180 (1) (1)   21 (1)   58 (0) (0) 
Current  
medication use:11 Acetaminophen    2,008 (52)   12,520 (37) (52)   996 (33)   3,545 (22) (31) 
  Non-study aspirin12   0 (0)   0 (0) (0)   462 (15)   2,636 (17) (19) 
  Statins   122 (3)   1,062 (3) (3)   647 (22)   3,525 (22) (24) 
                
 
            
 
1Baseline covariate values for prediction of initiation of any NSAID among women with eligible 12-mo post-randomization questionnaires 
2Updated covariate values for prediction of initiation of any NSAID among women with eligible 1-yr post-trial observational questionnaires  
3Non-initations were standardized to the initiations using stabilized weights constructed from the propensity score to control for confounding. 
The propensity score contained all covariates shown plus 2-year calendar time period of the questionnaire index date and interaction of all 
covariates with 2-year calendar time periods. 
4Number of women that were eligible to initiate and provided NSAID use data on the specified questionnaire 
5Confirmed cancer except non-melanoma skin cancer 
6Confirmed myocardial infarction, coronary artery bypass graft, percutaneous angioplasty, angina, stroke, carotid endarterectomy, or 
transient ischemic attack. Thirteen (13) women who enrolled into the study having reported no history of cardiovascular disease were later 
discovered to have had myocardial infarction, coronary revascularization, or stroke prior to enrollment by medical records review. The 
remaining cases of heart or cerebrovascular disease prior to randomization were either incident cases that occurred during the run-in period, 
or women discovered to have had angina or transient ischemic attack prior to enrollment.  
7Non-disconfirmed reported congestive heart failure, self-reported asthma or other self-reported chronic lung disease 
8Self-reported physician diagnosis, self-reported use of antihypertensive medication, or self-reported systolic blood pressure  ≥140 mmHg or 
diastolic ≥90 mmHg 
9Self-reported physician diagnosis or use of antidiabetic medications or insulin verified with the participant (see methods).  
10First lifetime diagnosis during the initiation eligibility period 
114+ days during the past month  12Non-study aspirin and/or aspirin containing medications. Non-regular use was required for study entry.  







Table 4.3. Risk (%) and risk difference for VTE within 2 yrs of NSAID initiation or non-initiation using 
as treated and initial treatment designs 
  2-yr Risk (%)1   2-yr RD (%) (95% CI)1 




initiationWT   Crude Adjusted 
              
As treated             
Any NSAID 0.36 0.23 0.25   0.12  (0.05, 0.21) 0.11  (0.03, 0.19) 
Traditional NSAIDs 0.32 0.23 0.24   0.09  (0.01, 0.17) 0.08  (0.00, 0.17) 
Coxibs 0.64 0.27 0.32   0.37  (0.07, 0.71) 0.32  (0.02, 0.66) 
              
Initial treatment             
Any NSAID 0.36 0.26 0.28   0.09  (0.03, 0.16) 0.08  (0.02, 0.14) 
Traditional NSAIDs 0.33 0.26 0.27   0.07  (0.01, 0.14) 0.06  (0.00, 0.13) 
Coxibs 0.59 0.29 0.35   0.30  (0.06, 0.53) 0.24  (0.00, 0.48) 
              
12-yr risks (expressed as percentages) and RDs were estimated from crude and stabilized SMR weighted survival 
curves. RDs were adjusted by standardizing the non-initiations to the initiations by all variables in the PS. 
Abbreviations: VTE= venous thromboembolism, NSAID= non-steroidal anti-inflammatory drugs, WT= weighted, RD= 







Table 4.4. Incidence rates and hazard ratios for VTE comparing NSAID initiation with non-initiation using as 
treated and initial treatment designs 
  Initiation   Non-initiation   HR (95% CI)1   
  Events2 PY IR   Events PY IR   Crude Adjusted   
                        
As treated                        
Any NSAID 140 76,649 1.8  1,284 1,081,357 1.2  1.5 (1.3, 1.9) 1.5 (1.2, 1.8)   
Traditional NSAIDs 98 60,732 1.6  1,269 1,070,375 1.2  1.4 (1.1, 1.7) 1.3 (1.1, 1.7)   
Coxibs 24 7,484 3.2  744 556,977 1.3  2.4 (1.6, 3.6) 2.0 (1.3, 3.1)   
                        
Initial treatment                       
Any NSAID 312 173,611 1.8  1,903 1,314,498 1.4  1.2 (1.1, 1.4) 1.2 (1.0, 1.3)   
Traditional NSAIDs 252 147,029 1.7  1,876 1,303,529 1.4  1.2 (1.0, 1.4) 1.1 (1.0, 1.3)   
Coxibs 51 18,945 2.7  1,070 678,905 1.6  1.7 (1.3, 2.3) 1.4 (1.1, 1.9)   
                        
1HRs were estimated using Cox proportional hazard models and adjusted by standardizing the non-initiations to the initiations 
on all covariates in the propensity score. At-risk follow-up time was restricted to maximum 5 years for all analyses.   
2VTE events (deep vein thrombosis, pulmonary embolus, or both) 
Abbreviations: VTE venous thromboembolism, NSAID= non-steroidal anti-inflammatory drugs, HR= hazard ratio, CI= 








Table 4.5. Hazard ratios for VTE comparing NSAID initiation with non-initiation stratified by frequency of 
use at time of initiation using as treated design 
  Initiation   Non-initiation   HR (95% CI)1   
  Events2 PY IR   Events PY IR   Crude Adjusted   
                        
Traditional NSAIDs                       
4-20 days/mo 73 46,726 1.6   1,269 1,070,375 1.2   1.3 (1.0, 1.7) 1.3 (1.0, 1.7)   
21+ days/mo 25 14,005 1.8   1,269 1,070,375 1.2   1.5 (1.0, 2.3) 1.3 (0.9, 2.0)   
                        
Coxibs                       
4-20 days/mo 7 2,360 3.0   396 293,331 1.4   2.2 (1.0, 4.6) 1.9 (0.9, 4.1)   
21+ days/mo 16 4,698 3.4   744 556,977 1.3   2.5 (1.5, 4.2) 2.0 (1.2, 3.4)   
                        
1 HRs were estimated using Cox proportional hazard models and adjusted by standardizing the non-initiations to the initiations 
on all covariates in the PS. As treated follow-up time was defined as continued use at 4+days/mo for both initial frequency 
categories. At-risk follow-up time was restricted to maximum 5 yrs for all analyses, except coxibs initiating at 4-20 days/mo was 
restricted to 2 yrs because the proportional hazard assumption was not met after 2 yrs.  
2VTE events (deep vein thrombosis, pulmonary embolus, or both)  
Abbreviations: VTE venous thromboembolism, NSAID= non-steroidal anti-inflammatory drugs, HR= hazard ratio, CI= 









Table 4.6. Risk (%), risk difference, and number needed to treat for VTE within 2 yrs of NSAID initiation or non-
initiation using as treated active comparator design 
 2-yr Risk (%)
1 




 Initiation Comparator ComparatorWT  Crude Adjusted  Adjusted 
                  
Coxibs vs.   
 traditional NSAIDs 0.64 0.36 0.38  0.28 (-0.02, 0.65) 0.26 (-0.09, 0.63) 
  
NNTH 386 
          
Any NSAID vs.    
acetaminophen 0.39 0.31 0.37  0.09 (-0.09, 0.27) 0.03 (-0.46, 0.14) 
  
NNTH 3,826 
          
Traditional NSAIDs  
vs. acetaminophen 0.36 0.31 0.37  0.05 (-0.15, 0.25) -0.01 (-0.55, 0.12) 
  
NNTB 10,766 
          
Coxibs vs.  
acetaminophen 0.61 0.40 0.50  0.20 (-0.25, 0.79) 0.11 (-0.43, 0.73) 
 
NNTH 937 
                  
12-yr risks (expressed as percentage), RDs, and NNTH/NNTB were estimated from crude and stabilized SMR weighted survival curves. 
RDs and NNTs were adjusted by standardizing the non-initiations to the initiations by all variables in the PS. 
2The null value of RD=0 corresponds to null value of NNT=infinity. A negative value for RD corresponds to NNTB. The 95% confidence 
limits for NNTH/NNTB are equal to the inverse of the 95% confidence limits of the adjusted RD. 
Abbreviations: VTE venous thromboembolism, NSAID= non-steroidal anti-inflammatory drugs, RD= risk difference, CI= confidence interval, 
NNTH/NNTB= number needed to treat for one additional woman to be harmed (NNTH) or to benefit (NNTB), WT= weighted, SMR= 








Table 4.7. Incidence rates and hazard ratios for VTE comparing initiation of NSAID with initiation of active 
comparator using as treated design 
  NSAID   Comparator    HR (95% CI)1   
  Events2 PY IR   Events PY IR   Crude Adjusted   
                        
Coxibs vs.   
 traditional NSAIDs 24 7,484 3.2   58 33,499 1.7   1.8 (1.1, 3.0) 1.8 (1.1, 2.9)   
                        
Any NSAID vs.    
acetaminophen 47 25,363 1.9   36 22,036 1.6   1.1 (0.7, 1.8) 0.9 (0.6, 1.5)   
                        
Traditional NSAIDs vs.   
acetaminophen 34 20,154 1.7   36 22,036 1.6   1.0 (0.6, 1.7) 0.9 (0.5, 1.5)   
                        
Coxibs vs.  
acetaminophen 8 2,341 3.4   22 10,683 2.1   1.7 (0.7, 3.7) 1.3 (0.5, 3.2)   
                        
1HRs were estimated using Cox proportional hazard models and adjusted by standardizing the non-initiations to the initiations on all 
covariates in the PS. At-risk follow-up time was restricted to maximum 5 yrs for all analyses, except coxibs vs. acetaminophen was 
restricted to 2 yrs because the proportional hazard assumption was not met after 2 yrs. All active comparator analyses were 
restricted to comparable calendar time period after availability of coxibs. Non-use of the comparator medication was required for 
each analysis. Regular use for was defined as response of 4+ days/mo use in the past month for all medications.  
2VTE events (deep vein thrombosis, pulmonary embolus, or both) 
Abbreviations: VTE venous thromboembolism, NSAID= non-steroidal anti-inflammatory drugs, HR= hazard ratio, CI= confidence 














PY IR Events PY IR Crude Adjusted
  Any NSAID v. non-initation 
Main analysis* 140 76,649 1.8 1,284 1,081,357 1.2 1.5 (1.3, 1.9) 1.5 (1.2, 1.8)
Restricted to women without history of VTE at study entry 124 74,298 1.7 1,192 1,055,752 1.1 1.5 (1.2, 1.8) 1.5 (1.2, 1.8)
Restricted to eligibility period length < 27mo 138 75,468 1.8 1,278 1,075,824 1.2 1.5 (1.3, 1.9) 1.5 (1.2, 1.8)
  Traditional NSAIDs v. non-initiation
Main analysis* 98 60,732 1.6 1,269 1,070,375 1.2 1.4 (1.1, 1.7) 1.3 (1.1, 1.7)
Restricted to women without history of VTE at study entry 87 58,919 1.5 1,177 1,045,123 1.1 1.3 (1.0, 1.7) 1.3 (1.0, 1.7)
Restricted to eligibility period length < 27mo 97 59,951 1.6 1,263 1,064,964 1.2 1.4 (1.1, 1.7) 1.3 (1.1, 1.7)
  Coxibs v. non-initiation
Main analysis* 24 7,484 3.2 744 556,977 1.3 2.4 (1.6, 3.6) 2.0 (1.3, 3.1)
Restricted to women without history of VTE at study entry 22 7,227 3.0 706 544,337 1.3 2.3 (1.5, 3.6) 2.0 (1.2, 3.1)
Restricted to eligibility period length < 27mo 23 7,297 3.2 739 552,680 1.3 2.3 (1.5, 3.6) 2.0 (1.3, 3.1)
Table S2. Sensitivity analysis: As treated hazard ratios for venous thromboembolism comparing NSAID initation with non-initiation for 
selected subgroups, Women's Health Study, 1999-2010
1
NSAID initiation Non-inititaion HR (95% CI)
1VTE events (deep vein thrombosis, pulmonary embolus, or both)    
Abbreviations: VTE= venous thromboembolism, NSAID= non-steroidal anti-inflammatory drug, HR= hazard ratio, CI= confidence interval, PY= person-years, IR= 







Table 4.9. Sensitivity analysis: As treated and initial treatment incidence rates and hazard ratios for VTE 




PY IR Events PY IR Crude Adjusted
  As treated
Any NSAID 2 yrs 98 54,597 1.8 631 537,583 1.2 1.5 (1.2, 1.9) 1.5 (1.2, 1.8)
3 yrs 113 64,863 1.7 879 751,010 1.2 1.5 (1.2, 1.8) 1.4 (1.1, 1.8)
5 yrs* 140 76,649 1.8 1,284 1,081,357 1.2 1.5 (1.3, 1.9) 1.5 (1.2, 1.8)
Unlimited 157 89,644 1.8 2,008 1,678,878 1.2 1.5 (1.2, 1.8) 1.4 (1.2, 1.7)
Traditional NSAIDs 2 yrs 74 45,137 1.6 626 532,139 1.2 1.4 (1.1, 1.8) 1.3 (1.0, 1.7)
3 yrs 83 52,747 1.6 872 743,289 1.2 1.3 (1.0, 1.7) 1.3 (1.0, 1.7)
5 yrs* 98 60,732 1.6 1,269 1,070,375 1.2 1.4 (1.1, 1.7) 1.3 (1.1, 1.7)
Unlimited 106 67,047 1.6 1,989 1,663,354 1.2 1.3 (1.1, 1.7) 1.3 (1.0, 1.6)
Coxibs 2 yrs 18 5,696 3.2 396 293,331 1.4 2.3 (1.4, 3.8) 2.0 (1.2, 3.2)
3 yrs 21 6,617 3.2 538 402,869 1.3 2.4 (1.5, 3.7) 2.0 (1.3, 3.1)
5 yrs* 24 7,484 3.2 744 556,977 1.3 2.4 (1.6, 3.6) 2.0 (1.3, 3.1)
Unlimited 25 7,985 3.1 894 706,298 1.3 2.4 (1.6, 3.6) 2.0 (1.3, 3.1)
  Initial treatment
Any NSAID 2 yrs 134 75,188 1.8 744 568,567 1.3 1.4 (1.1, 1.6) 1.3 (1.1, 1.6)
3 yrs 192 110,420 1.7 1,135 834,920 1.4 1.3 (1.1, 1.5) 1.2 (1.0, 1.4)
5 yrs* 312 173,611 1.8 1,903 1,314,498 1.4 1.2 (1.1, 1.4) 1.2 (1.0, 1.3)
Unlimited 603 338,473 1.8 4,268 2,703,724 1.6 1.1 (1.0, 1.2) 1.0 (0.9, 1.1)
Traditional NSAIDs 2 yrs 106 63,698 1.7 728 563,203 1.3 1.3 (1.0, 1.6) 1.2 (1.0, 1.5)
3 yrs 152 93,560 1.6 1,116 827,396 1.3 1.2 (1.0, 1.4) 1.2 (1.0, 1.4)
5 yrs* 252 147,029 1.7 1,876 1,303,529 1.4 1.2 (1.0, 1.4) 1.1 (1.0, 1.3)
Unlimited 510 295,598 1.7 4,235 2,687,542 1.6 1.1 (1.0, 1.2) 1.0 (0.9, 1.1)
Coxibs 2 yrs 24 8,075 3.0 460 311,701 1.5 2.0 (1.3, 3.0) 1.7 (1.1, 2.6)
3 yrs 35 11,904 2.9 685 450,819 1.5 1.9 (1.4, 2.7) 1.6 (1.2, 2.3)
5 yrs* 51 18,945 2.7 1,070 678,905 1.6 1.7 (1.3, 2.3) 1.4 (1.1, 1.9)
Unlimited 80 31,482 2.5 1,496 977,132 1.5 1.7 (1.3, 2.1) 1.4 (1.1, 1.8)
Table S3.1. Sensitivity analysis: As treated and initial treatment incidence rates and hazard ratios for venous thromboembolism 
comparing NSAID initiation with non-initiation by length of at-risk follow-up time restriction, Women's Health Study, 1993-2010.
Initiation Non-initation HR (95% CI)
1
VTE events (deep vein thrombosis, pulmonary embolus, or both)    
Abbreviations: VTE= venous thromboembolism, NSAID= non-steroidal anti-inflammatory drug, HR= hazard ratio, CI= confidence 






Table 4.10. Sensitivity analysis: As treated hazard ratios for VTE comparing initiation of NSAID with initiation of active 




PY IR Events PY IR Crude Adjusted
  Coxibs vs. traditional NSAIDs
2 yrs 18 5,696 3.2 48 25,418 1.9 1.7 (1.0, 2.9) 1.6 (0.9, 2.8)
3 yrs 21 6,617 3.2 52 29,553 1.8 1.8 (1.1, 3.0) 1.8 (1.0, 3.0)
5 yrs* 24 7,484 3.2 58 33,499 1.7 1.8 (1.1, 3.0) 1.8 (1.1, 2.9)
Unlimited 25 7,985 3.1 59 35,547 1.7 1.9 (1.2, 3.0) 1.8 (1.1, 3.0)
  Any NSAID  vs acetaminophen
2 yrs 39 19,711 2.0 29 18,004 1.6 1.2 (0.8, 2.0) 1.1 (0.7, 1.9)
3 yrs 43 22,590 1.9 33 20,154 1.6 1.2 (0.7, 1.8) 1.0 (0.6, 1.6)
5 yrs* 47 25,363 1.9 36 22,036 1.6 1.1 (0.7, 1.8) 0.9 (0.6, 1.5)
Unlimited 50 27,293 1.8 37 23,267 1.6 1.2 (0.8, 1.8) 1.0 (0.6, 1.5)
  Traditional NSAIDs vs acetaminophen
2 yrs 28 16,173 1.7 29 18,004 1.6 1.1 (0.6, 1.8) 1.0 (0.6, 1.7)
3 yrs 32 18,293 1.7 33 20,154 1.6 1.1 (0.7, 1.7) 0.9 (0.5, 1.5)
5 yrs* 34 20,154 1.7 36 22,036 1.6 1.0 (0.6, 1.7) 0.9 (0.5, 1.5)
Unlimited 36 21,205 1.7 37 23,267 1.6 1.1 (0.7, 1.7) 0.9 (0.5, 1.5)
  Coxibs vs. acetaminophen
2 yrs* 8 2,341 3.4 22 10,683 2.1 1.7 (0.7, 3.7) 1.3 (0.5, 3.2)
3 yrs 8 2,643 3.0 24 11,878 2.0 1.5 (0.7, 3.4) 1.2 (0.5, 2.8)
5 yrs 8 2,903 2.8 26 12,796 2.0 1.4 (0.6, 3.0) 0.9 (0.4, 2.2)
Unlimited 8 3,046 2.6 27 13,227 2.0 1.3 (0.6, 2.9) 0.9 (0.4, 2.1)
Table S3.2. Sensitivity analysis: As treated hazard ratios for venous thromboembolism comparing initation of NSAID with 
initiation of active comparator by length of maximum follow-up time restriction, Women's Health Study, 2000-2010.
NSAID Active Comparator HR (95% CI)
1
1
Analyses of Coxibs vs traditional NSAIDs and acetaminophen were restricted for both groups to calendar time period after availability 
of coxibs. Non-use of the comparator medication was required for each analysis. Regular use for all medications was defined as 
response of 4+ days/month used in the past month. 
2
VTE events (deep vein thrombosis, pulmonary embolus, or both)   
Abbreviations: VTE= venous thromboembolism, NSAID= non-steroidal anti-inflammatory drugs, HR= hazard ratio, CI= confidence 






Table 4.11. Sensitivity analysis: As treated hazard ratios for VTE comparing initiation of NSAID with non-initiation by 





PY IR Events PY IR Crude Adjusted
  Traditional NSAIDs 
4-20 days/mo 2 yrs 56 35,409 1.6 626 532,139 1.2 1.3 (1.0, 1.8) 1.3 (1.0, 1.8)
3 yrs 61 40,993 1.5 872 743,289 1.2 1.3 (1.0, 1.6) 1.3 (1.0, 1.7)
5 yrs* 73 46,726 1.6 1,269 1,070,375 1.2 1.3 (1.0, 1.7) 1.3 (1.0, 1.7)
Unlimited 76 51,074 1.5 1,989 1,663,354 1.2 1.2 (1.0, 1.6) 1.3 (1.0, 1.6)
21+ days/mo
2 yrs 18 9,728 1.9 626 532,139 1.2 1.6 (1.0, 2.5) 1.4 (0.8, 2.2)
3 yrs 22 11,753 1.9 872 743,289 1.2 1.6 (1.0, 2.4) 1.4 (0.9, 2.2)
5 yrs* 25 14,005 1.8 1,269 1,070,375 1.2 1.5 (1.0, 2.3) 1.3 (0.9, 2.0)
Unlimited 30 15,973 1.9 1,989 1,663,354 1.2 1.6 (1.1, 2.3) 1.4 (0.9, 2.0)
  Coxibs
4-20 days/mo 2 yrs* 7 2,360 3.0 396 293,331 1.4 2.2 (1.0, 4.6) 1.9 (0.9, 4.1)
3 yrs 8 2,590 3.1 538 402,869 1.3 2.3 (1.1, 4.6) 2.0 (1.0, 4.1)
5 yrs 8 2,787 2.9 744 556,977 1.3 2.1 (1.0, 4.3) 1.9 (0.9, 3.8)
Unlimited 8 2,877 2.8 894 706,298 1.3 2.1 (1.0, 4.2) 1.8 (0.9, 3.8)
21+ days/mo 2 yrs 11 3,336 3.3 396 293,331 1.4 2.4 (1.3, 4.5) 2.0 (1.1, 3.7)
3 yrs 13 4,027 3.2 538 402,869 1.3 2.4 (1.4, 4.2) 1.9 (1.1, 3.4)
5 yrs* 16 4,698 3.4 744 556,977 1.3 2.5 (1.5, 4.2) 2.0 (1.2, 3.4)
Unlimited 17 5,108 3.3 894 706,298 1.3 2.5 (1.5, 4.2) 2.0 (1.2, 3.4)
1
VTE events (deep vein thrombosis, pulmonary embolus, or both)    
Abbreviations: VTE= venous thromboembolism, NSAID= non-steroidal anti-inflammatory drug, HR= hazard ratio, CI= confidence 
interval, PY= person-years, IR= crude incidence rate per 1,000 PY   *Reported in manuscript
Table S3.3. Sensitivity analysis: As treated hazard ratios for venous thromboembolism comparing initation of NSAID with non-
initiation by frequency of use at initation and length of maximum follow-up time restriction, Women's Health Study, 2000-2010.






Table 4.12. Summary of pharmacoepidemiologic studies of NSAID use and VTE 
First author 
Publication Yr 
Study design & time period 
Data source Confounding control 
Measure of effect  
Exposure  




Cohort 1987-1999  
ARIC and CHS (U.S.) 
Multivariable model- sex, age, 
race 
Adjusted HR 
Use vs. non-use1 
VTE (DVT or PE) 
Traditional NSAIDS 





General Practice Research 
Database (U.K.) 
Matching- sex, age   
Multivariable model- race, BMI, 
calendar year, smoking, selected 
comorbidities 
Adjusted OR 
Current use vs. never 
use 
VTE (DVT or PE) 
All NSAIDs 
     1.9 (1.7, 2.1) 
Use duration <30 days:   




Case-control 1990-2006  
PHARMO Record Linkage 
System (The Netherlands) 
Matching- sex, age, region 
Multivariable model- hospital 
comorbidities, comedications 
Adjusted OR 




      2.4 (2.1, 2.8) 
Use duration <30 days: 




Case-control 1999-2006  
Danish National Patient 
Registry (Denmark) 
Matching- sex, age 
Multivariable model- obesity, 
numerous comorbidities and 
comedications 
Adjusted IRR 
Current use vs. 
current non-use 
VTE (DVT or PE) 
Non-selective NSAIDs 
      2.6 (2.3, 2.8) 
Use duration <60 days: 
      4.5 (3.9, 5.4) 
 
Coxibs 
      2.2 (2.0, 2.4) 
Use duration <60 days: 








Restricted to women 
Adjusted OR 
Current use vs. 
current non-use 
Hospitalized first-time 
DVT or PE 
All NSAIDs 
     1.0 (0.8, 1.2) 
Coxibs 









The Health Improvement 
Network (United Kingdom) 
Matching – sex, age, calendar 
index date 
Multivariable model- obesity, 
smoking, comorbidities, health 
care utilization indicators 
Restricted to patients with knee 
OA diagnosis and ≥ 1 NSAID 
prescription 
 
Adjusted OR  
Current (<60 days) or 
recent (60-365 days)    
vs. remote use (>365 
days ago)  
VTE (DVT of PE) 
 
Any NSAID  
  Current 1.4 (1.3, 1.4) 
   Recent 1.4 (1.4, 1.5) 
(use of > 1 NSAID type 
excluded)  
1 ‘Use’ and ‘non-use’ were not defined 
Abbreviations: ARIC= Atherosclerosis Risk in Communities, CHS= Cardiovascular Health Study, BMI= body mass index, VTE= 
venous thromboembolism, DVT= deep vein thrombosis, PE= pulmonary embolism, OR= odds ratio, HR= hazard ratio , IRR= 
incidence rate ratio, NSAID = non-steroidal anti-inflammatory drug, OA = osteoarthritis 
 
 56 
Figure 4.1. Flow diagram depicting the derivation of the study sample for the main 




enrolled into the WHS
324,124 questionnaires
of 38,493 women 
included in primary analysis
*Collected at baseline only
401,634 questionnaires




returned after first incident VTE
Excluded: 
23,109 questionnaires with
no follow-up time after index date 
(e.g., woman’s last WHS questionnaire) 
Excluded: 
8,469 questionnaires with
missing data for one or more covariates
Number questionnaires with missing data:
5,000 - Education*   
2,760 - Race*
318 - Hormone replacement therapy
175 - Smoking
151 - Body mass index
75 - Menopausal status
36 - Alcohol consumption
27 - Statin use
6 - Physical exercise
5 - Acetaminophen use
3 - Multivitamin use
Excluded: 
42,597 questionnaires without coxib
question returned after 12/31/1998
Number (%) excluded by questionnaire: 
12 months - 0     (0%)
24 months - 1     (0%)
36 months - 202     (1%)
48 months - 3,741    (13%)
60 months - 12,981    (48%)
72 months - 25,672  (100%) 
90 women had 
no NSAID use data after study entry
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Figure 4.2 Weighted Kaplan-Meier curves for time to first confirmed VTE event in non-
initiation comparator analyses 
showing initiation (blue) vs. non-initiation (red) of any NSAID (A, B), traditional NSAIDs (C, D), 
and coxibs (E, F) with as treated and initial treatment designs, respectively.  
 
The weighted counts remaining at risk for time t are shown. For initiations, the weighted count is 
equal to the number of questionnaires; for non-initiations, it is the sum of the stabilized SMR 































Figure 4.3 Weighted Kaplan-Meier survival curves for time to first confirmed VTE event in 
active comparator analyses  
showing initiation (blue) vs. comparator initiation (red) of coxibs vs. traditional NSAIDs (A), and 
any NSAID (B), traditional NSAIDs (C), and coxibs (D) vs. acetaminophen with as treated 
designs  
 
The weighted counts remaining at risk for time t are shown. For initiations, the weighted count is 
equal to the number of questionnaires; for comparator initiations, it is the sum of the stabilized 






















CHAPTER 5. DESIGN AND ANALYTIC APPROACHES TO UNMEASURED CONFOUNDING 
OF THE ASSOCIATION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUG 
INITIATION AND VENOUS THROMBOEMBOLISM BY BODY MASS INDEX 
 
5.1. Introduction 
 Body mass index (BMI), often an important potential confounder in 
pharmacoepidemiologic studies, is unavailable in insurance claims data and its prediction is 
difficult. Claims-based case definitions and risk scores to identify obesity have been developed, 
but their suitability for use in confounding control is limited by poor specificitysensitivity.49,50 The 
association of obesity with increased risk of venous thromboembolism (VTE) is well-
established,7,28,29,35 as is the association of obesity with pain,40-42 the principal indication for the 
use of non-steroidal anti-inflammatory drugs (NSAIDs). Associations of NSAID use with VTE 
incidence in non-experimental studies are therefore likely to be confounded by obesity. 
 There is increasing interest in internal validation via linkage to electronic health records 
(EHR) systems to augment claims data in pharmacoepidemiologic research.10-12 Multiple 
imputation13 (MI) is one viable approach in such situations.14 An active comparator design can 
improve referent group comparability without a requirement for additional data or statistical 
procedures, but its interpretation is context-specific.15,16 Using data from the Women’s Health 
Study (WHS), we sought to describe confounding of the association of NSAID initiation and VTE 
by BMI compared with non-initiation and initiation of acetaminophen, an active comparator with 
similar indications but without known hemostatic effects. Specifically, we explored approaches 
to control for unmeasured confounding by mimicking a claims data analysis with BMI values 




Data source and study design 
 This analysis extends upon a previous study by these authors of the incidence of VTE 
following initiation of NSAID use among WHS participants (see Chapter 4). Briefly, from 1993 to 
1995 the WHS randomized 39,876 female health professionals aged 45 years and older to a 
regimen of low dose aspirin or placebo and vitamin E or placebo for primary prevention of 
cancer and cardiovascular disease. The study excluded women who were using NSAIDs more 
than once per week. Women were followed annually via written questionnaires, which included 
number of days NSAIDs were used in the past month and incident VTE since the last 
questionnaire. A separate question for use of cyclooxygenase-2 inhibitors (coxibs) were 
implemented after the U.S. commercial release of coxibs in 1998. We focused on the 
association of traditional NSAIDs with VTE for the current study, described on the WHS 
questionnaire as, “Nonsteroidal anti-inflammatory agents (e.g., Motrin, Advil, Naprosyn, 
Feldene, Nuprin, Aleve)”. We counted only VTE events confirmed by an endpoint committee. 
Yearly questionnaires from study inception through 7 years post trial (1993 through 2011) were 
available for our analysis.  
 We constructed a new user design99 from the sequential WHS questionnaires to 
evaluate the association of NSAID initiation with VTE. The unit of analysis was the 
questionnaire.64,89 We designed as-treated analyses with non-initiation (NIC) and 
acetaminophen initiation (AIC) comparators. The NIC compared initiators of traditional NSAIDs 
without coxibs to non-initiators of any non-aspirin NSAID, and the AIC compared initiation of 
traditional NSAIDs without coxibs or acetaminophen to initiation of acetaminophen without any 
non-aspirin NSAID. We defined initiation as the first report of regular medication use (4 days in 
the past month) following study entry or a washout period of 2 or more consecutive reports of 
non-regular use of any non-aspirin NSAID spanning at least 18 months. For AIC, the washout 
also required non-regular use of acetaminophen. At-risk follow-up periods for VTE began on the 
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questionnaire date. The at-risk follow-up time for each questionnaire was censored on the 
earliest of the first report of treatment change (stopping, switching, or augmenting); death not 
from VTE; withdrawal; end of study follow-up; or 5 years after the eligible questionnaire date. 
We restricted the analyses to questionnaires with complete data (no missing values) for all 
covariates used in the PS or imputation models. Seven hundred seventy-six (0.24%) and 49 
(0.18%) questionnaires were excluded for one or missing covariate values from the NIC and 
AIC analyses, respectively. The NIC cohort included 323,006 questionnaires of 39,454 women, 
and the AIC cohort included 25,966 questionnaires of 19,313 women.  
 We created scenarios in the NIC analysis with BMI data missing from the primary data 
source but attainable for internal validation samples (VS) (e.g., a claims analysis supplemented 
by electronic health records) to evaluate the performance of MI under missing completely at 
random (MCAR), missing at random (MAR), and missing not at random (MNAR) scenarios. We 
created MCAR internal VSs of 0.01 to 0.90 proportion of the full cohort sample and designed 
analyses to impute BMI for the complement to the full sample, and to incrementally decrease 
the complement portions while retaining fixed absolute VS sizes of 0.05, 0.10, 0.20, and 0.30 
proportions. The latter was intended to explore the effect of changing the size of the total 
sample while holding the absolute size of the VS fixed.  
 We created an MAR scenario with missingness of BMI data in the EMR was correlated 
with the absence vs. presence of baseline comorbidities, defined as pre-study or incident 
comorbidities reported on or before each woman’s earliest eligible questionnaire (0 vs.  1 of 
the following: cardiovascular, cardiopulmonary, or cerebrovascular disease, malignant cancer, 
hypertension, diabetes, atrial fibrillation, coagulation disorder, gastrointestinal bleeding or peptic 
ulcer disease, osteoarthritis, rheumatoid arthritis, fractures or joint replacements, osteoporosis, 
or migraine headaches), and an MNAR scenario where missingness was correlated with the 
value of BMI (normal:18.5-25 vs. non-normal: <18.5 or > 25)100 and. We implemented 
probabilities of selection within the binary strata that would create relative risks of missingness 
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of BMI data (RR(missing)) of 1.5, 3.0, 5.0, and 10.0 using VS proportions of 0.03, 0.05, 0.10, 
and 0.30 of the full sample. We posited that women with clinically normal compared with non-
normal BMI and fewer compared with more health conditions may have fewer encounters with 
health care delivery systems as well as a lower probability of having BMI recorded during a 
given health care encounter.101 The cut point of  1 vs. 0 comorbidities was selected based on 
the distribution of comorbidities on each woman’s first questionnaire date in the NIC population; 
22,454 (57%) women had 0 and 17,000 (43%) had ≥1 baseline comorbidity. Hypertension (33% 
of women), osteoarthritis (18%), cardiopulmonary (11%, includes asthma), and migraine 
headaches (7%) were most common. Baseline BMI was normal for 19,606 women (50%) and 
non-normal for 19,848 (50%). 
Sampling methods 
 We created MCAR VSs via simple random sampling without replacement using a 
random sort method. The unit of sampling was the woman. We enumerated the sampling frame 
(39,545 individual women) according to a uniformly distributed pseudo-random number, then 
obtained VSs by selecting the first n elements (women) in the frame needed to create specified 
validation sample sizes expressed as proportions of the full sample (e.g., n = validation sample 
size (proportion) x 39,454, rounded down). To mimic MAR and MNAR VSs, we created 
separate consecutive enumerations for each binary stratum of baseline BMI and comorbidity 
presence for stratified simple random sampling. The same MCAR and MNAR enumerations 
were used for all subsampling; thus, each increasingly larger sample wholly contained all 
women of the smaller sample(s). The VS population therefore changes in a nested fashion as 
VS proportion changes.  
Analytic methods 
 We estimated fully adjusted, BMI-naïve, and crude hazard ratios (HR) with 95% 
confidence intervals (CI) for NIC and AIC using Cox proportional hazard models with a robust 
variance to account for multiple questionnaires of the same woman. Propensity scores (PS) 
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incorporating age, BMI (specified as BMI and BMI squared), and relevant comorbidities and 
concurrent medications updated over time were estimated using logistic regression models, 
then used to construct stabilized weights to standardize the comparator group to the NSAID 
initiation group on all covariates in the PS for confounding control.68  
 The MI analyses were performed using fully conditional specification with 50 
imputations.102 The imputation model was restricted to the earliest eligible questionnaire of each 
woman, which represented a scenario of acquiring a matched value for each woman’s baseline 
BMI from the EHR source. For women selected for the validation sample, we carried the 
baseline BMI value forward to all subsequent questionnaires; for women not selected for the 
validation sample, we imputed BMI and BMI squared for each questionnaire based on the 
updated covariate values. We imputed BMI followed by BMI squared using linear regression, 
treating the squared term as ‘just another variable’.103,104 The distribution of BMI was right-
skewed (Figures 5.1, 5.2), however we used the original values of BMI and BMI squared as 
dependent variables for the imputation models to preserve the linear relationships expressed in 
the analysis model105 and to avoid bias related to back transformation. von Hippel (2012) 
demonstrated in simulations that bias of regression coefficients from multiply imputing positively 
skewed variables under a normal model was generally mild.106  
 We compared MI with the fully adjusted and BMI-naïve analysis in terms of change of 
estimate and qualitative trends and compared MI with complete case (CC) analyses 
qualitatively. The CC analyses included all questionnaires of all women selected for the 
validation sample using baseline BMI values carried forward to all subsequent questionnaires. 
We described imputation model performance in terms of magnitude, variance, and the 
probability of a non-positive value of the estimated coefficient (point estimate) for both NSAIDs 
initiation and VTE (both binary indicators) on BMI (dependent variable), as well as the observed 
sign of the estimated coefficients over the 50 imputations. Probability of the coefficient value ≤0 
(Pr(ß≤0)) was calculated from a standard normal distribution using the estimated coefficient and 
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its standard error obtained from a regular linear regression model. Based on prior knowledge of 
established associations of BMI with VTE and pain, we hypothesized that the prediction model 
should predict higher BMI for both NSAID initiation and outcome of VTE to accurately represent 
the underlying model of confounding in the population. We repeated the analysis using a 
different pseudo-random number seed to generate the SRS samples as a sensitivity analysis. 
SAS 9.4 software (SAS Institute, Cary, NC) was used for all analyses. 
Model selection 
 The initial PS model was the model we used in our substantive study of NSAID initiation 
and VTE (see Chapter 4). Our objective was to identify a simplified PS model including BMI that 
could control for confounding with effectiveness similar to the initial model. To mimic a claims 
analysis scenario, we excluded the following covariates used in our main study that are typically 
unavailable in claims data: race, educational attainment, smoking, alcohol consumption, 
physical exercise, multivitamin use, and menopausal status; however, we included all 
medications of interest, whether prescription and non-prescription. The final PS model 
contained age (5-year categories), BMI, ever/never history of cardiovascular disease, malignant 
cancer, diabetes, atrial fibrillation, gastrointestinal bleeding or peptic ulcer disease, migraine 
headaches, previous history or concurrent new diagnosis of rheumatoid or osteoarthritis, 
concurrent use of acetaminophen and non-study aspirin, history of PE before study entry, 
calendar year of questionnaire index date (1994-1998, 1999-2004, or 2005-2010), and 
interaction of calendar year category with all medical comorbidities and concurrent medications 
(Table 5.1). BMI was specified as a continuous variable and operationalized as a first order and 
squared term in the PS. The c-statistic for the final PS model was 0.627 for the full cohort NIC 
and 0.628 for the AIC analysis. We assessed the final PS by graphical analysis and examination 
of covariate balance (Figure 5.3). 
 The linear regression imputation model for prediction of BMI in the NIC cohort was 
identified using a forward selection approach considering influence of individual variable(s) in 
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the model in terms of parameter estimates, variance, and t statistic, and change of adjusted R2. 
To preserve the variable relationships represented in the analysis model, we entered all 
independent variables of the PS model except BMI, BMI squared, calendar time, and 
interactions with calendar time into the initial imputation model using identical variable 
specifications, plus binary indicators of the exposure (initiation of traditional NSAIDs vs. non-
initiation of any NSAID) and outcome (VTE during the as-treated follow-up period vs. 
censor).107,108 We also included time to VTE event or censor108 and additional variables that 
improved prediction including prevalent or incident diseases and concurrent medication uses. 
Calendar time could not be represented in the imputation model because we only included each 
woman’s earliest questionnaire. The final model included 22 variables plus interactions 
operationalized as 45 parameters (Table 5.2).  
5.3. Results 
Reference estimates 
 Confounding by BMI was evident in bivariate analyses (Figures 5.1, 5.2) and in the final 
models in terms of change of the estimated ln(HR) and change of the c-statistic for the PS 
model (Table 5.3). Our fully adjusted NIC (95% CI) HR using known time-varying BMI was 1.29 
(1.03, 1.62). The adjusted NIC HR using known baseline BMI was 1.31 (1.04, 1.65), and the 
BMI-naïve HR 1.36 (1.06, 1.66), representing 1.3% and 5.4% changes of estimate, respectively. 
The AIC was more robust to the absence of BMI than NIC [fully adjusted AIC HR using time-
varying BMI: 0.88 (0.54,1.45), BMI naïve HR: 0.91 (0.55, 1.48), change of estimate=2.6%]. The 
adjusted AIC also showed residual bias with the use of baseline compared with time varying 
BMI (adjusted AIC HR using baseline BMI=0.90, change of estimate=1.6%).  
Missing completely at random 
 Prediction of BMI was poor: adjusted R2 was 0.160 for the fully adjusted model using all 
questionnaires of all women with time-varying BMI and calendar time interaction (Figure 5.4), 
and 0.146 or less for the imputation models (Table 5.5, Figure 5.5). Our sampling produced 
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imputation model samples with less than 10 total VTE events for VS proportions ≤0.05 of full 
sample (Table 5.4). Compared with the adjusted NIC HR using baseline BMI [HR 1.31, 
confidence limit ratio (CLR) 1.58)], CC HRs were biased downward for VS proportions 0.40 to 
0.90 (HR range 1.19 to 1.25) and upward for VS proportions 0.30 and smaller (HR range 1.47 to 
5.39). 
 In contrast, MI HRs and their variances were extremely consistent (HR range 1.30-1.31, 
CLR all 1.58) for VS proportions 0.30 and larger and only modestly biased for VS proportions 
0.04 to 0.10 (HR range 1.29 to 1.33 representing -1.3% to 1.7% change of estimate, CLR range 
1.61 to 1.74). In the imputation models, model coefficients for initiation were increased and 
coefficients for VTE were decreased from the full (100% sample) model values for all VS 
proportions 0.10 and smaller with coefficients for VTE <0 for most VS proportions less than 0.10 
(Table 5.5). Despite poor prediction and low event counts in the VSs, MI HRs were less biased 
than the BMI-naïve comparator model (HR= 1.36) for all but the smallest VS proportion of 0.01, 
which contained only 1 exposed and 1 unexposed VTE event in the imputation model.  
  Variation of the imputed portion of the total sample using fixed absolute VS sizes 
showed that the incremental trend for each VS proportion from full sample to CC analysis was 
similar across the VS proportions we included (Table 5.6).  
Missing at random and missing not at random 
 When missingness was correlated with the value of BMI (18-25 vs. <18 or >25), the MI 
HR showed slightly increasing upward bias with increasing RR(missing) for VS proportion of 
0.30 (MCAR HR 1.30, MNAR HRs 1.32-1.33). VS proportions 0.10 and smaller showed greater 
variation and no clear trend, with 6 of 12 MNAR HRs outside the range of 1.31 to 1.36 (HRs of 
the full baseline BMI-adjusted and BMI-naïve models) (Table 5.7). The findings were similar for 




 Analyses repeated using an alternate seed to generate the VSs showed similar overall 
patterns except that event counts in most VSs and imputation models were smaller, and loss of 
imputation model performance in the smallest VS proportions was manifested in the form of 
negative model coefficients for initiation and very large regression coefficients for VTE (Tables 
5.9, 5.10). The differences of these patterns between the main and sensitivity analyses 
corresponded with differences of the distributions of BMI among the small number of individuals 
with events remaining in the imputation model (data not shown). MI HRs showed a slight 
decreasing trend with stable variance with decreasing VS proportion through 0.20 that changed 
to a highly variable pattern with increased variance for VS samples ≤0.10, which coincided with 
0 exposed events in the imputation model. Failure of the imputation model to predict higher BMI 
for both BMI and VTE again coincided with total VTE event count < 10 in the imputation model. 
Trends with incremental changes of total sample size (Table 5.11) and MAR and MNAR 
scenarios (data not shown) were qualitatively similar to the main analysis.  
5.4. Discussion 
Overview 
 We aimed to mimic a claims analysis of the association of NSAID initiation and VTE with 
BMI available from EHR linkage using long-term cohort data from the WHS to explore the 
effectiveness of approaches to unmeasured confounding. Despite poor prediction, MI performed 
well with larger VS proportions (i.e.,  0.30) and better than CC analyses in all situations. 
Examples of MI performing worse than the BMI-naïve analysis coincided with failure of the 
imputation model to predict the correct direction of confounding associations and/or lack of at 
least one VTE event in each exposure group in the imputation model. Our AIC analysis was 
more robust to the absence of BMI than the NIC analysis, while addressing a different (and 
perhaps better) research question. 
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Implications for pharmacoepidemiology 
 MI relies on the ability to predict the missing data from the observed data.13 However, 
accurate prediction of BMI of adults from administrative claims data is difficult.50 We could 
achieve improved prediction (adjusted R square =0.210 compared with 0.160) with the addition 
of smoking, alcohol consumption, physical exercise (met-hours/wk), multivitamin use, and 
menopausal status from the WHS to our prediction model. Juak, et. al. (2018) described 
prediction of BMI in EHR data using demographic, medical, and laboratory data available from 
the EHR in linear regression models that was qualitatively better than our model supplemented 
with lifestyle variables (i.e., modestly improved graphical correlation of recorded vs predicted 
values).48 The performance of the imputation model is frequently unmentioned in studies that 
utilize MI for missing BMI, even some studies focused on approaches for missing BMI.109,110  
 In most situations, our MI models produced HRs between those of the baseline BMI-
adjusted and BMI naïve reference models, indicating achievement of at least partial 
confounding control. Spurious results in the smallest VS proportions coincided with poor 
imputation model performance that was empirically evident from the regression parameters. Our 
study illustrates the value of deliberate examination of the imputation model in the 
implementation of MI. In situations where the expected directions of the associations of a 
missing confounder with both exposure and outcome are well-informed by prior knowledge, the 
model’s effectiveness of representing the expected associations can to some extent be 
assessed empirically. However, our examples were limited to a single missing confounder and 
admittedly simple scenarios. This assessment would be less straightforward in the presence of 
compound missing data patterns, more complex specifications of exposure or outcome, or 
treatment effect heterogeneity. 
 The value of an active comparator design in the setting of unmeasured confounding can 
easily be overlooked in the search for statistical solutions. Restriction to individuals with 
indication for treatment increases the similarity of the groups on both measured and 
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unmeasured characteristics.16 In other words: once the decision for treatment of chronic pain is 
made (which might depend on BMI), BMI does not further affect the decision which analgesic to 
take or prescribe.16 Practical benefits include reduction of confounding by factors that are 
unmeasured or difficult to measure, and improvement of the contrast in terms of clinical 
relevance15,51 without a need for additional data or statistical procedures. Huitfeldt, et. al. 
argued, that under certain conditions with the right comparator, an observational new user 
active comparator design could emulate a placebo-controlled randomized controlled trial.52 
Though a woman’s decision to take acetaminophen vs. a traditional NSAID is not perfectly 
exchangeable in all situations, our AIC represents a reasonable design because initiators of 
both share a common treatment indication while acetaminophen use is not suspected of 
influencing VTE risk.52  
Strengths and Limitations 
 The WHS provided a unique opportunity to explore a hypothetical scenario of a claims 
data analysis augmented by EHR to obtain BMI data for a subset of observations with known 
BMI values for all women available for comparison. However, our study has several limitations. 
First, though BMI was an important confounder in the association of NSAID initiation and VTE, 
the strength of confounding by BMI in the main study was modest for the comparisons we 
aimed to elucidate. Changes of HR estimates in response to differences of models were of 
subclinical magnitude and sometimes difficult to distinguish from sample-to-sample variation. 
Our observations are of one set of randomly selected subsamples, corroborated by a second 
set as sensitivity analysis. Thus, our observations regarding possible thresholds for 
performance should be interpreted as hypothesis generating. A resampling approach that could 
describe the distributions of results over multiple VS generations may be useful but would be 
computationally intensive. The new user design of our analytic study treats each questionnaire 
as the unit of analysis with questionnaires spanning almost 2 decades. The translation of this 
design to a hypothetical claims data analysis with baseline BMI obtainable from EHR linkage 
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may not mirror a realistic situation, however the availability of a single, non-time specific value 
from an external data source is plausible. In the case of adult BMI, a value for an individual at 
an earlier time can be expected to predict BMI at a different time more accurately than 
demographic and medical covariates (Figure 5.6).111  
Conclusion 
 Our MI approaches showed potential to control confounding by BMI with internal 
validation data in most situations despite suboptimal prediction and small VTE event counts. An 
active comparator analysis can improve the quality of comparison in the setting of unmeasured 
confounding without additional data or statistical procedures. MI approaches broke down with 
few outcome events in the validation study, however, and we encourage detailed assessment 




5.5. Tables and Figures 
 
Table 5.1.Variables selected for the propensity score model for control of confounding in 
the estimation of hazard ratio for VTE  
Variable Specification  # terms 
Age 8 5-yr categories  7 
Body mass index (BMI) & BMI squared 2 continuous terms  2 
First lifetime incidence before initiation eligibility period, ever/never :   
Confirmed cardiovascular disease1 binary  1 
Confirmed cancer (except non-melanoma skin cancer) binary  1 
Diabetes binary  1 
Atrial fibrillation binary  1 
Gastrointestinal bleeding or peptic ulcer disease binary  1 
Migraine headaches binary  1 
Osteoarthritis or rheumatoid arthritis2 binary  1 
First lifetime incidence during initiation eligibility period, yes/no:3   
Osteoarthritis or rheumatoid arthritis2 binary  1 
Current medication use (4+ days of the past month):    
Acetaminophen4 binary  1 
Non-study aspirin or aspirin containing medications binary  1 
Other:    













Interaction of all incident disease and medication use 
variables with calendar time 
20 binary 
interaction terms  20 
1Myocardial infarction, unstable angina, coronary artery bypass graft, stroke, transient 
ischemic attacks, or carotid endarterectomy 
2Physician diagnosed (self-reported) 
3Temporal order of disease incidence and NSAID initiation cannot be established when 
both occur during the initiation eligibility period. However, we included this variable 
because it was influential in the PS (in terms of change of c-statistic and change of 
estimate for the adjusted hazard ratio), and it seems implausible that NSAID initiation could 
cause incident arthritis. 
4Omitted from PS for acetaminophen active comparator cohort 
5Year of questionnaire date. Calendar time periods were selected based on clinically 
relevant temporal events (introduction and withdrawal of coxibs from the U.S. market). 




Table 5.2. Variables selected for the imputation model for prediction of BMI 
Variable Specification  # terms 
All variables in the PS model  
 except BMI, BMI squared, 
calendar time category, 
 and calendar time interactions1 
Identical to 
PS model  18 
NSAID initiation (exposure) binary  1 
Confirmed VTE during at-risk follow-up (outcome)  binary  1 
Time to outcome or censor (yrs)2 continuous  1 
    
First lifetime incidence before initiation eligibility period, ever/never:   
Hypertension binary  1 
Osteoporosis binary  1 
Orthopedic event (joint replacement or fracture) binary  1 
Cardiopulmonary disease binary  1 
Coagulation disorder binary  1 
First lifetime incidence during initiation eligibility period, yes/no:   
Cardiovascular disease, cancer, diabetes, atrial 
fibrillation, gastrointestinal bleeding or peptic ulcer 
disease, migraine headaches, hypertension, 
osteoporosis, orthopedic event, cardiopulmonary 
disease, coagulation disorder 
binary  11 
Current medication use:    
Statins binary  1 
Hormone replacement therapy current/past/never  2 
Other:    
Interaction of diabetes with:  
hypertension, cardiovascular disease; cancer; 




1The representation of calendar time and calendar time interactions in the propensity score 
model could not be preserved in the imputation model because only each woman’s earliest 
questionnaire was used for the imputation model. 
2In the survival analysis the outcome is comprised of time t and the censoring indicator d. 
See: White, et. al. (2011)108 
Abbreviations: BMI=body mass index; PS=propensity score, NSAID= non-steroidal anti-







Table 5.3. Fully adjusted, BMI-naïve, and crude hazard ratios for VTE comparing initiation of traditional NSAIDs with non-
initiation of any NSAID and initiation of acetaminophen 
  
Initiations Non-initiations
VTE No VTE PY IR VTE No VTE PY IR  HR (95% CI)
1
CLR ln(Hr)
Initiation of traditional NSAIDs vs non-initiation of any NSAID (non-user comparator)
Fully Adjusted, updated BMI 98 32,684 62,096 16 1,302 288,922 1,095,513 12 1.29  (1.03, 1.62) 1.58 0.255 ref ref 0.627
Fully Adjusted, baseline BMI2 1.31  (1.04, 1.64) 1.58 0.268 0.013 1.3% 0.625
BMI removed 1.36  (1.08, 1.71) 1.58 0.308 0.053 5.4% 0.620
Crude 1.33  (1.06, 1.66) 1.56 0.282 0.026 2.7%
Initiation of traditional NSAIDs vs initiation of acetaminophen (active comparator)
Fully Adjusted, updated BMI 34 12,185 20,592 17 36 13,711 22,486 16 0.88  (0.54, 1.45) 2.68 -0.124 ref ref 0.628
Fully Adjusted, baseline BMI 0.90  (0.55, 1.47) 2.68 -0.108 0.016 1.6% 0.628
BMI removed 0.91  (0.55, 1.48) 2.68 -0.098 0.026 2.6% 0.627
Crude 1.03  (0.65, 1.65) 2.55 0.032 0.156 16.8%
Table 1. Fully adjusted, BMI-naive, and crude hazard ratios for VTE comparing initiation of traditional NSAIDs to non-initiation of any NSAID 
with initiation of acetaminophen.
1Estimated from Cox proportional hazard models with the comparator group standardized to the NSAID initiation group using inverse probability weights 
constructed from a PS that contained age (5-year categories); BMI and BMI squared; ever/never history of cardiovascular disease, malignant cancer, diabetes, 
atrial fibrillation, gastrointestinal bleeding or peptic ulcer disease, and migraine headaches; previous history or concurrent new diagnosis of rheumatoid or 
osteoarthritis; concurrent use of acetaminophen and non-study aspirin; history of VTE before study entry; calendar year of questionnaire index date (1994-1998, 
1999-2004, or 2005-2010); and interaction of calendar year category with all medical comorbidities and concurrent medications. 
2The fully adjusted model with baseline BMI carries initial BMI forward to all subsequent questionnaires while the fully adjusted model with updated BMI incorporates 
time-varying BMI values available in the WHS which are updated over time.
Abbreviations: BMI=body mass index, VTE=venous thromboembolism, NSAID=non-steroidal antiinflammatory drug, PY=person-yrs, IR=incidence rate per 10,000 
















Table 5.4. Estimation of adjusted hazard ratios for VTE comparing initiation of traditional NSAIDs with non-initiation of any 
NSAID with multiple imputation using MCAR internal validation samples 
  
Complete Case Analysis1 Multiple Imputation2
Initiations Non-initiations
VTE No VTE PY IR VTE No VTE PY IR  CC HR (95% CI)
4
CLR MI HR (95% CI)
4
CLR ln(HR) HR %
1.00 98 32,684 62,096 16 1,302 288,922 1,095,513 12 1.31  (1.04, 1.64) 1.58 ref ref
0.90 88 29,460 55,987 16 1,213 259,740 984,838 12 1.23  (0.97, 1.56) 1.61 1.31  (1.04, 1.65) 1.58 0.003 0.3%
0.80 78 26,244 49,833 16 1,083 231,133 876,612 12 1.21  (0.94, 1.56) 1.66 1.31  (1.04, 1.65) 1.58 0.004 0.4%
0.70 66 22,994 43,724 15 924 202,512 768,401 12 1.20  (0.91, 1.58) 1.73 1.31  (1.05, 1.65) 1.58 0.005 0.5%
0.60 55 19,782 37,561 15 772 173,358 657,584 12 1.21  (0.90, 1.64) 1.82 1.31  (1.04, 1.65) 1.58 0.002 0.2%
0.50 43 16,424 31,217 14 628 144,590 548,520 11 1.19  (0.85, 1.67) 1.97 1.31  (1.04, 1.65) 1.58 0.004 0.4%
0.40 35 13,143 25,028 14 504 115,386 437,379 12 1.25  (0.86, 1.83) 2.13 1.31  (1.04, 1.65) 1.58 0.004 0.4%
0.30 31 9,911 18,868 16 364 86,194 326,718 11 1.53  (1.02, 2.32) 2.28 1.30  (1.04, 1.64) 1.58 -0.002 -0.2%
0.20 20 6,602 12,440 16 239 57,171 216,260 11 1.47  (0.89, 2.44) 2.74 1.29  (1.02, 1.64) 1.61 -0.013 -1.3%
0.10 11 3,280 6,098 18 131 28,760 108,960 12 1.49  (0.75, 2.97) 3.96 1.31  (1.04, 1.67) 1.61 0.005 0.5%
0.05 6 1,650 3,051 20 51 14,505 54,877 9 2.42  (0.89, 6.54) 7.32 1.33  (1.02, 1.74) 1.70 0.017 1.7%
0.04 4 1,308 2,428 16 39 11,610 44,008 9 1.95  (0.59, 6.45) 10.89 1.32  (1.00, 1.74) 1.74 0.010 1.0%
0.03 3 988 1,830 16 20 8,669 32,767 6 2.77  (0.62, 12.32) 19.83 1.35  (0.99, 1.84) 1.86 0.031 3.1%
0.02 3 658 1,211 25 20 5,780 21,935 9 2.56  (0.56, 11.70) 20.86 1.34  (0.99, 1.81) 1.83 0.024 2.4%
0.01 2 338 621 32 10 2,939 11,111 9 5.39  (0.69, 41.90) 60.50 1.39  (0.97, 2.00) 2.06 0.063 6.5%
Table 2. Estimation of adjusted hazard ratios for VTE comparing initiation of traditional NSAIDs with non-initiation of any NSAID with multiple 







1Complete case analyses included all questionnaires of women selected for the VS with baseline BMI carried forward to all questionnaires. 
2The earliest questionnaire of each woman selected for the validation sample was used for the imputation model. The fulll study population (323,006 questionnaires 
of 39,454 women) was used to estimate all MI HRs. For women in the validation sample, baseline BMI was carried forward to all subsequent questionnaires. For 
women not in the validation sample, BMI for each questionnaire wasmultiply imputed with 50 imputations. 
3Change of MI ln(HR) or % change of HR from full adjusted model using baseline BMI [HR(95%CI)= 1.31 (1.04,1.64), ln(HR)=0.26801] 
4All HRs were estimated using Cox proportional hazard models with the comparator group standardized to the NSAID initiation group using inverse probability 
weights constructed from a PS that contained age (5-year categories); BMI and BMI squared; ever/never history of cardiovascular disease, malignant cancer, 
diabetes, atrial fibrillation, gastrointestinal bleeding or peptic ulcer disease, and migraine headaches; previous history or concurrent new diagnosis of rheumatoid or 
osteoarthritis; concurrent use of acetaminophen and non-study aspirin; and history of VTE before study entry.
Abbreviations: VTE=venous thromboembolism, NSAID=non-steroidal antiinflammatory drug, MCAR= missing completely at random, BMI=body mass index, 
IR=incidence rate per 10,000 years, CC= complete cases, MI= multiple imputation,  HR=hazard ratio, CI=confidence interval, CLR=confidence interval ratio, 
ref=reference
















Table 5.6. Estimation of adjusted hazard ratios of VTE for traditional NSAID initiation vs. non-initiation using multiple 
imputation with MCAR validation samples of fixed absolute sizes with incremental changes of total sample size 
  
0.30 0.20 0.10 0.05
Validation sample (numbers)
Women 11,836 7,890 3,945 1,972
Questionnaires 96,500 64,032 32,182 16,212
Imputation model (numbers)2
Initiations with VTE / no VTE 7 / 1,238 4 / 821 1 / 413 1 / 196
Non-initiations with VTE / no VTE 45 / 10,546 30 / 7,035 19 / 3,512 7 / 1,768
MI HR (95%CI) CLR by total sample size
Proportion
 of full sample1
Total number of
 questionnaires3
1.00 323,006 1.30   (1.04, 1.64) 1.58 1.29   (1.02, 1.64) 1.61 1.31   (1.04, 1.67) 1.61 1.33   (1.02, 1.74) 1.70
0.90 290,501 1.25   (0.98, 1.58) 1.62 1.23   (0.96, 1.57) 1.63 1.25   (0.97, 1.60) 1.65 1.27   (0.96, 1.69) 1.75
0.80 258,538 1.23   (0.95, 1.58) 1.67 1.21   (0.94, 1.57) 1.68 1.22   (0.94, 1.59) 1.69 1.23   (0.92, 1.65) 1.79
0.70 226,496 1.22   (0.93, 1.61) 1.74 1.21   (0.92, 1.60) 1.75 1.23   (0.93, 1.62) 1.75 1.24   (0.91, 1.68) 1.85
0.60 193,967 1.24   (0.92, 1.68) 1.83 1.23   (0.90, 1.67) 1.84 1.24   (0.91, 1.69) 1.85 1.28   (0.93, 1.76) 1.89
0.50 161,685 1.22   (0.87, 1.71) 1.97 1.21   (0.86, 1.70) 1.98 1.21   (0.85, 1.70) 1.99 1.22   (0.85, 1.76) 2.06
0.40 129,068 1.29   (0.88, 1.88) 2.13 1.27   (0.87, 1.86) 2.14 1.29   (0.88, 1.90) 2.15 1.30   (0.88, 1.94) 2.22
0.30 96,500 1.53   (1.02, 2.32) 2.28 1.58   (1.04, 2.38) 2.29 1.60   (1.05, 2.42) 2.30 1.60   (1.04, 2.47) 2.38
0.20 64,032 1.47   (0.89, 2.44) 2.74 1.55   (0.93, 2.57) 2.76 1.56   (0.93, 2.64) 2.84
0.10 32,182 1.49   (0.75, 2.97) 3.96 1.61   (0.81, 3.22) 4.00
0.05 16,211 2.42   (0.89, 6.54) 7.32
Table 4. Estimation of adjusted hazard ratios of VTE for traditional NSAID initiation vs. non-initiation using multiple imputation with 
MCAR validation samples of fixed absolute sizes with incremental changes of total sample size
Validation sample as proportion of full sample1
1Proportion of women randomly selected from sampling frame of 39,454 women.
2The earliest questionnaire of each selected woman was used in the imputation model to predict BMI.
Abbreviations: VTE=venous thromboembolism, NSAID=non-steroidal antiinflammatory drug, MCAR= missing completely at random, MI= multiple 






Table 5.7. Performance of multiple imputation under MNAR scenarios of greater missingness of BMI in the EHR correlated 
with normal values of BMI (normal: 18.5-25 vs. non-normal: <18.5 or >25 kg/m2) 
  





(missing) VTE No VTE PY IR VTE No VTE PY IR HR (95% CI) CLR ln(HR) HR %
.30 1.5 6 1,256 2,522 24 48 10,525 42,876 11 1.32    (1.05, 1.66) 1.58 0.007 0.7%
.30 3.0 6 1,290 2,563 23 50 10,489 42,489 12 1.33    (1.06, 1.67) 1.58 0.018 1.8%
.30 5.0 5 1,315 2,607 19 51 10,464 42,253 12 1.33    (1.06, 1.67) 1.58 0.019 1.9%
.30 10.0 5 1,339 2,672 19 52 10,440 41,962 12 1.33    (1.06, 1.68) 1.58 0.020 2.0%
.10 1.5 2 426 824 24 18 3,498 14,288 13 1.27    (1.00, 1.61) 1.61 -0.028 -2.8%
.10 3.0 2 442 861 23 18 3,483 14,106 13 1.31    (1.04, 1.66) 1.61 0.004 0.4%
.10 5.0 2 453 894 22 17 3,472 14,003 12 1.29    (1.01, 1.65) 1.64 -0.013 -1.3%
.10 10.0 2 458 916 22 18 3,466 13,914 13 1.33    (1.04, 1.70) 1.62 0.017 1.8%
.05 1.5 1 201 386 26 10 1,760 7,140 14 1.35    (1.05, 1.73) 1.65 0.030 3.1%
.05 3.0 1 209 411 24 10 1,752 7,083 14 1.31    (1.03, 1.67) 1.62 0.004 0.4%
.05 5.0 1 221 444 23 10 1,740 7,033 14 1.32    (1.04, 1.67) 1.61 0.008 0.8%
.05 10.0 1 220 439 23 9 1,742 7,015 13 1.32    (1.04, 1.68) 1.62 0.011 1.1%
.03 1.5 1 121 227 44 5 1,055 4,317 12 1.29    (0.93, 1.78) 1.90 -0.016 -1.5%
.03 3.0 1 132 258 39 4 1,046 4,251 9 1.36    (1.04, 1.78) 1.71 0.040 4.1%
.03 5.0 1 127 255 39 5 1,050 4,239 12 1.37    (1.03, 1.81) 1.76 0.045 4.6%





Table 5. Performance of multiple imputation under MNAR scenarios of greater missingness of BMI in the EHR correlated 
with normal values of BMI (normal: 18.5-25 vs. non-normal: <18.5 or >25 kg/m2)
1The earliest questionnaire of each woman selected for the VS was used for the imputation model.
2The fulll study population (323,006 questionnaires of 39,454 women) was used to estimate all MI HRs.
3Change of MI ln(HR) or % change of HR from full sample baseline BMI-adjusted model [HR(95%CI)= 1.31 (1.04,1.64), ln(HR)=0.26801] 
Abbreviations: VTE=venous thromboembolism, NSAID=non-steroidal antiinflammatory drug, MNAR= missing not at random, BMI=body mass 
index, EHR= electronic health records, PY=person yrs, IR=crude incidence rate per 10,000 person-yrs, HR=hazard ratio,  CI=confidence 
interval,  RR= relative risk
Change from full 
model adjusted






Table 5.8. Performance of multiple imputation under MAR scenarios of greater missingness of BMI in the EHR correlated 
with absence of prevalent comorbidities (0 vs. ≥1 of 14 possible) 
  





(missing) VTE No VTE PY IR VTE No VTE PY IR HR (95% CI) CLR ln(HR) HR %
.30 1.5 6 1,314 2,652 23 46 10,469 42,682 11 1.30    (1.03, 1.64) 1.58 -0.005 -0.5%
.30 3.0 6 1,400 2,817 21 45 10,385 42,069 11 1.31    (1.04, 1.65) 1.58 0.004 0.4%
.30 5.0 6 1,451 2,921 21 43 10,335 41,631 10 1.32    (1.05, 1.65) 1.58 0.006 0.6%
.30 10.0 6 1,495 3,009 20 41 10,294 41,388 10 1.32    (1.05, 1.66) 1.58 0.010 1.0%
.10 1.5 3 440 858 35 16 3,485 14,191 11 1.32    (1.05, 1.67) 1.59 0.009 0.9%
.10 3.0 3 483 972 31 14 3,445 13,920 10 1.37    (1.08, 1.73) 1.60 0.045 4.6%
.10 5.0 3 489 998 30 13 3,439 13,881 9 1.38    (1.09, 1.74) 1.60 0.053 5.5%
.10 10.0 3 513 1,062 28 12 3,416 13,698 9 1.37    (1.09, 1.73) 1.60 0.048 5.0%
.05 1.5 1 208 392 26 8 1,754 7,128 11 1.33    (1.04, 1.71) 1.65 0.018 1.9%
.05 3.0 1 227 437 23 6 1,738 7,049 9 1.35    (1.04, 1.74) 1.67 0.029 2.9%
.05 5.0 1 239 474 21 6 1,726 6,986 9 1.35    (1.05, 1.72) 1.63 0.030 3.0%
.05 10.0 1 249 499 20 6 1,715 6,936 9 1.31    (1.00, 1.72) 1.72 0.002 0.2%
.03 1.5 1 128 247 40 5 1,049 4,307 12 1.32    (0.98, 1.77) 1.80 0.006 0.6%
.03 3.0 1 142 270 37 4 1,036 4,229 9 1.33    (0.99, 1.78) 1.80 0.014 1.4%
.03 5.0 1 144 278 36 4 1,033 4,190 10 1.28    (0.94, 1.74) 1.85 -0.021 -2.0%
.03 10.0 1 148 284 35 3 1,031 4,166 7 1.29    (0.93, 1.78) 1.92 -0.016 -1.6%
1The earliest questionnaire of each woman selected for the VS was used for the imputation model.
2The fulll study population (323,006 questionnaires of 39,454 women) was used to estimate all MI HRs. 
3Change of MI ln(HR) or % change of HR from full sample baseline BMI-adjusted model [HR(95%CI)= 1.31 (1.04,1.64), ln(HR)=0.26801] 
Abbreviations: VTE=venous thromboembolism, NSAID=non-steroidal antiinflammatory drug, MNAR= missing not at random, BMI=body mass 
index, EHR= electronic health records, PY=person yrs, IR=crude incidence rate per 10,000 person-yrs, HR=hazard ratio,  CI=confidence 
interval,  RR= relative risk
Table S3. Performance of multiple imputation under MNAR scenarios of greater missingness of BMI in the EHR correlated 





Change from full 
model adjusted






Table 5.9. Sensitivity Analysis: Estimation of adjusted hazard ratios using multiple imputation with MCAR internal validation 
samples 
using alternate pseudo-random number seed to generate simple random samples  
  
Complete Case Analysis1 Multiple Imputation2
Initiations Non-initiations
VTE No VTE PY IR VTE No VTE PY IR  CC HR (95% CI)
4
CLR MI HR (95% CI)
4
CLR ln(HR) HR %
1.00 98 32,684 62,096 16 1,302 288,922 1,095,513 12 1.31  (1.04, 1.64) 1.58 ref ref
0.90 87 29,502 55,986 16 1,160 259,747 984,243 12 1.27  (1.00, 1.62) 1.62 1.31  (1.04, 1.64) 1.58 -0.002 -0.2%
0.80 74 26,233 49,797 15 1,030 230,878 874,985 12 1.21  (0.94, 1.58) 1.68 1.31  (1.04, 1.64) 1.58 -0.002 -0.2%
0.70 65 22,857 43,374 15 899 202,109 765,885 12 1.24  (0.94, 1.64) 1.74 1.31  (1.04, 1.64) 1.58 0.000 0.0%
0.60 54 19,641 37,181 15 786 173,311 656,824 12 1.19  (0.88, 1.61) 1.83 1.30  (1.04, 1.64) 1.58 -0.002 -0.2%
0.50 47 16,384 30,951 15 638 144,572 548,143 12 1.28  (0.92, 1.78) 1.92 1.29  (1.03, 1.62) 1.58 -0.011 -1.1%
0.40 39 13,132 24,777 16 494 115,681 438,233 11 1.35  (0.94, 1.94) 2.07 1.30  (1.03, 1.64) 1.58 -0.005 -0.5%
0.30 30 9,848 18,567 16 345 87,035 330,268 10 1.43  (0.94, 2.18) 2.32 1.30  (1.04, 1.64) 1.58 -0.003 -0.3%
0.20 24 6,551 12,447 19 213 58,091 220,369 10 1.97  (1.21, 3.21) 2.65 1.30  (1.03, 1.65) 1.59 -0.002 -0.2%
0.10 10 3,251 6,212 16 119 29,059 110,589 11 1.43  (0.70, 2.95) 4.23 1.26  (0.98, 1.62) 1.66 -0.038 -3.7%
0.05 3 1,606 3,029 10 58 14,873 56,903 10 0.95  (0.27, 3.35) 12.45 1.32  (1.03, 1.70) 1.65 0.012 1.2%
0.04 1 1,284 2,377 4 39 12,057 46,157 8 0.59  (0.07, 4.89) 68.06 1.23  (0.78, 1.91) 2.44 -0.065 -6.3%
0.03 0 972 1,783 0 32 9,028 34,451 9 not estimable 1.14  (0.74, 1.76) 2.38 -0.135 -12.7%
0.02 0 621 1,107 0 20 6,101 23,460 9 not estimable 1.05  (0.50, 2.20) 4.43 -0.222 -19.9%
0.01 0 293 509 0 12 3,008 11,492 10 not estimable 1.36  (1.08, 1.73) 1.60 0.043 4.4%
1Complete case analyses included all questionnaires of women selected for the VS with baseline BMI carried forward to all questionnaires. 
2The earliest questionnaire of each woman selected for the validation sample was used for the imputation model. The fulll study population (323,006 questionnaires 
of 39,454 women) was used to estimate all MI HRs. For women in the validation sample, baseline BMI was carried forward to all subsequent questionnaires. For 
women not in the validation sample, BMI for each questionnaire wasmultiply imputed with 50 imputations. 
3Change of MI ln(HR) or % change of HR from full adjusted model using baseline BMI [HR(95%CI)= 1.31 (1.04,1.64), ln(HR)=0.26801] 
Abbreviations: VTE=venous thromboembolism, NSAID=non-steroidal antiinflammatory drug, MCAR= missing completely at random, BMI=body mass index, 
IR=incidence rate per 10,000 years, CC= complete cases, MI= multiple imputation,  HR=hazard ratio, CI=confidence interval, CLR=confidence interval ratio, 
ref=reference
Table 2. Estimation of adjusted hazard ratios for VTE comparing initiation of traditional NSAIDs with non-initiation of any NSAID with multiple 
imputation using MCAR internal validation samples














Table 5.10. Sensitivity Analysis: Imputation model parameters for prediction of BMI using MCAR validation samples 







Table 5.11. Sensitivity Analysis: Estimation of adjusted hazard ratios using multiple imputation with MCAR validation 
samples of fixed absolute sizes with incremental changes of total sample size 
using alternate pseudo-random number seed to generate simple random samples  
 
0.30 0.20 0.10 0.05
Validation sample (numbers)
Women 11,836 7,890 3,945 1,972
Questionnaires 97,258 64,879 32,439 16,540
Imputation model (numbers)2
Initiations with VTE / no VTE 7 / 1,238 4 / 821 1 / 413 1 / 196
Non-initiations with VTE / no VTE 45 / 10,546 30 / 7,035 19 / 3,512 7 / 1,768
MI HR (95%CI) CLR by total sample size
Proportion
 of full sample1
Total number of
 questionnaires
1.00 323,006 1.30   (1.04, 1.64) 1.58 1.30   (1.03, 1.65) 1.59 1.26   (0.98, 1.62) 1.66 1.32   (1.03, 1.70) 1.65
0.90 290,496 1.29   (1.01, 1.64) 1.63 1.29   (1.00, 1.65) 1.64 1.23   (0.95, 1.60) 1.68 1.31   (1.01, 1.70) 1.69
0.80 258,215 1.23   (0.95, 1.60) 1.69 1.23   (0.95, 1.61) 1.70 1.18   (0.90, 1.55) 1.74 1.24   (0.93, 1.64) 1.77
0.70 225,930 1.26   (0.95, 1.66) 1.75 1.26   (0.95, 1.67) 1.76 1.20   (0.89, 1.61) 1.80 1.27   (0.94, 1.72) 1.83
0.60 193,792 1.20   (0.89, 1.63) 1.84 1.20   (0.89, 1.63) 1.84 1.16   (0.84, 1.59) 1.88 1.23   (0.89, 1.70) 1.91
0.50 161,641 1.31   (0.94, 1.82) 1.93 1.31   (0.94, 1.82) 1.93 1.26   (0.90, 1.77) 1.96 1.32   (0.93, 1.85) 1.98
0.40 129,346 1.36   (0.94, 1.95) 2.07 1.36   (0.95, 1.97) 2.08 1.32   (0.91, 1.92) 2.09 1.38   (0.95, 2.00) 2.12
0.30 97,258 1.43   (0.94, 2.18) 2.32 1.44   (0.95, 2.20) 2.33 1.39   (0.90, 2.13) 2.36 1.45   (0.94, 2.22) 2.37
0.20 64,879 1.97   (1.21, 3.21) 2.65 1.95   (1.19, 3.20) 2.68 2.00   (1.22, 3.28) 2.70
0.10 32,439 1.43   (0.70, 2.95) 4.23 1.49   (0.72, 3.07) 4.27
0.05 16,540 0.95   (0.27, 3.35) 12.45
Table 4. Estimation of adjusted hazard ratios of VTE for traditional NSAID initiation vs. non-initiation using multiple imputation with 
MCAR validation samples of fixed absolute sizes with incremental changes of total sample size
Validation sample as proportion of full sample1
1Proportion of women randomly selected from sampling frame of 39,454 women.
2The earliest questionnaire of each selected woman was used in the imputation model to predict BMI.
Abbreviations: VTE=venous thromboembolism, NSAID=non-steroidal antiinflammatory drug, MCAR= missing completely at random, MI= multiple 
imputation, HR=hazard ratio, CI=confidence interval, CLR=confidence limit ratio
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Figure 5.1. Distribution of BMI in the NIC cohort by initiation 
from the earliest questionnaire of each woman 
 
Figure 5.2. Distribution of BMI among non-initiations the NIC cohort by VTE outcome 




Figure 5.3. Propensity score distributions before and after standardization, respectively, 
for NSAID initiation vs. non-initiation (A, B) and NSAID initiation vs. acetaminophen 
initiation (C, D)  
 
   A.       B.  
  






Figure 5.4. Scatterplot showing known BMI values plotted against values predicted from 
covariates in the 100% full sample for initiation vs. non-initiation of traditional NSAIDs 






Figure 5.5. Known vs. predicted BMI values among imputed questionnaires using 20% 
(A), 5% (B), and 1% (C) validation samples 
Plots are restricted to the complement portions (80%, 95%, and 99%, respectively) which were 

















Figure 5.6. Scatterplot showing last vs. first self-reported BMI value of all women in the 
NIC analysis  









CHAPTER 6. DISCUSSION 
 
6.1. NSAID use and VTE incidence 
 While high prevalence of NSAID use and clinical and public health significance of VTE 
underscore the importance of understanding their association, current understanding is limited 
and inconclusive. NSAID use has been implicated as a risk factor for VTE with relative risks on 
the order of 1.5-3.0 reported in multiple observational studies,2-8 but a biologic explanation for a 
causal effect is not clear. Previous studies have primarily evaluated prevalent NSAID use, 
though 3 case-control studies looked secondarily at prevalent exposure of shorter duration 
(‘new use’ or ‘recent use’) (see Chapter 4, Table 4.12). One older cohort study did not define 
‘use’.7 Due to the low event rate and large sample size requirement, it unlikely that a 
randomized trial of NSAID use and VTE outcomes will be undertaken.9  
 Our study represents several improvements upon previous non-experimental studies of 
NSAID use and VTE in terms of the data source, design characteristics, and methods. The 
WHS cohort was uniquely suited for the study of new use of NSAID for several reasons. 
Regular users of NSAIDs were excluded from the trial at baseline by design,57 therefore, an 
assumption that a first report of regular use represents ‘new use’ is plausible. This advantage 
was similarly leveraged in a study on the effects of NSAID initiation and duration of use on the 
risk for colon cancer in the Physician’s Health Study.112 Use of NSAIDs and other pain relievers 
were captured annually for the duration of follow-up including non-prescription medications 
which were unavailable in several previous studies of VTE outcomes. The ascertainment of VTE 
outcomes in the WHS was rigorous because VTE was a pre-declared secondary outcome of the 
trial. The rich covariate set of the WHS also conferred advantages for confounding control 
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compared to previous studies that relied on claims or other administrative data. Using a rich 
data source and robust methods for confounding control, we found that risk of VTE associated 
with NSAID use among women was not high. Comparing with initiation of acetaminophen, little 
risk from NSAID use was seen.  
 The new user design is the standard study design for pharmacoepidemiology and 
comparative effectiveness research,99 and cohort data are rich potential sources for 
pharmacoepidemiologic research. Hernan, et. al.64 demonstrated a novel implementation of a 
cohort-based new user design when assessing the effects of hormone therapy on 
cardiovascular disease outcomes in the Nurse’s Health Study, a long-term prospective cohort 
study. In addition to identifying and following new users from initiation of therapy, they created 
untreated comparator cohorts at every follow-up questionnaire from all women that had not (yet) 
initiated hormone therapy at that questionnaire. The study was thereby treated as a sequence of 
discrete ‘trials’ which were analyzed in pooled fashion using logistic regression. The authors 
argued that, under the assumption of no unmeasured confounding, this analytic strategy 
mimicked the RCT design of the Women’s Health Initiative. The CASCADE collaboration writing 
group (Jonsson-Funk, corresponding author) subsequently described the implementation of this 
approach in the context of time-to-event analysis in a study to evaluate the response of CD4 cell 
counts to initiation of highly active anti-retroviral therapy among participants of a longitudinal 
cohort study.65 Danaei, et. al. (2013) implemented sequential pooling of discrete observation 
periods from electronic medical records data using logistic regression in a study of the effect of 
statins for primary prevention of coronary heart disease.89 Our study represents one of the 
earliest implementations of this approach to a pharmacoepidemiologic research question, thus, 




6.2. Unmeasured confounding 
  Unmeasured confounding is a common challenge in non-experimental 
pharmacoepidemiologic studies, as many commonly used data sources lack measurements of 
important covariates such as obesity, smoking, and activity level. We sought to advance 
understanding of approaches for controlling unmeasured confounding by BMI in the scenario of 
a claims data analysis in a ‘real data’ experiment where the measured value of the confounder 
was available for comparison. A number of quantitative approaches to unmeasured confounding 
have been described, and each have caveats. One common approach we did not explore that 
does not rely on validation data involves calculating the strength of confounding that would be 
needed to explain the magnitude of an observed association.6,113 Multiple imputation is a 
longstanding methods for estimation of unmeasured values using internal validation samples, 
and is the standard approach for situations where outcome data are available.43,44 Our study 
provided an opportunity to observe and describe thresholds for effectiveness of MI with 
decreasing VS sizes and a rare outcome with increasingly spare event rates. With regard to 
describing thresholds for ineffectiveness of confounding control in settings of sparse VSs, our 
observations were specific to the particular sample and should not be interpreted as 
generalizable. Our study could benefit from a resampling approach to more accurately describe 
the correspondence of features of the sample with evidence of MI non-performance.  
 The implementation of an active comparator new user design to address a real-world 
need was a common theme of both aims of this work. An active comparator design effectively 
increases similarity of measured, unmeasured, and even impossible to measure group 
characteristics by restricting the study to individuals with the common treatment indication.51 
Practical benefits include reduction of confounding and increased clinical relevance of the 
research question.15,16 Moreover, these benefits are achieved without the need for external data 
sources and complex statistical procedures. It does, however, require a suitable active 
comparator, ideally one that shares a common indication for treatment in the observational 
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setting, and is believed not to influence the outcome of interest. Huitfeldt, et. al. argued, that 
under certain conditions with a suitable comparator, an observational active comparator design 
could emulate a placebo-controlled RCT.52 Acetaminophen and traditional NSAIDs are not 
perfectly exchangeable in terms of indication, but they are similar. Both are available without 
prescription for pain and fever, however NSAIDs differ from acetaminophen in terms of anti-
inflammatory action and risk of gastrotoxicity and other unintended effects. In the WHS, 
acetaminophen use was collected alongside NSAID use on every questionnaire using the same 
question format. Though acetaminophen in recommended dosages has been considered safe 
for decades, it is not guaranteed to have no effect on VTE. Some have suggested that it’s 
structural similarities to COX-2 inhibitors warrant concern for cardiovascular risks.114,115 
6.3. Public Health Implications 
 Pain is a major public health problem with enormous individual and societal costs.81 
Chronic pain negatively affects quality of life and general health, interferes with employment, 
daily activities, and relationships, and is associated with anxiety, depression, and increased 
consumption of health care.116 Gaskin, et. al. (2012) estimated from the 2008 Medical 
Expenditure Panel Survey that 100 million U.S. adults were affected by chronic pain with an 
estimated total annual cost burden of $560 to $635 billion ($261 to $300 billion in health care 
costs, plus $300 to $335 from lost productivity in 2010 U.S. dollars).117 
 There are only 2 main options for pharmacologic treatment of pain, NSAIDs and opioid 
analgesics, therefore NSAID use is extremely common. Zou, et. al. (2014) estimated from 
National Health Interview Survey data that 15% of U.S. women used NSAIDs at least 3 times 
per week for more than 3 months in 2010.79 Fosbøl, et. al. (2008) reported that 58% of all 
Danish citizens aged 10 years and older obtained at least one prescription for an NSAID from 
1997 to 2005.118 In the WHS, 10% of women reported using NSAIDs 4 or more days of the past 
month on the 12-month post-randomization questionnaire, just 1 year after confirming non-
regular use and agreeing to forgo the use of NSAIDs as a condition of enrollment into the study 
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(Figure 3.5). Three of four WHS participants reported using NSAIDs regularly at some time 
during the study.  
 The incidence and public health burden of VTE is less clearly understood due to under-
recognition in some settings and the difficulty of quantifying the indirect contribution of VTE to 
morbidity and mortality.18 However, evidence indicates that the global burden of disease in 
terms of mortality and disability is substantial, and is magnified in aging populations.119  
 The limited scope of treatment options for individuals with chronic pain81 coupled with 
national calls for improved prevention of VTE18 underscore the importance of defining the risk of 
VTE associated with NSAIDs. The opioid use epidemic that followed the commercial withdrawal 
of COX-2 selective NSAIDs after discovery of the cardiotoxic effects of coxibs in the early 2000s 
illustrate that the available alternatives for medical treatment of chronic pain are suboptimal.1,120 
For the many sufferers with chronic pain, effective pharmacologic treatment is not a luxury that 
can simply be done without in the interest of risk avoidance.  
 An accurate understanding of small but potentially serious risks associated with NSAID 
use is needed to correctly weigh the risks and benefits of treatment for individuals affected by 
pain, particularly in light of the high prevalence of exposure to NSAIDs. Pragmatically, the large 
sample size requirement for a randomized trial of the risk of VTE outcomes with NSAID use will 
necessitate that further work rely heavily on observational designs.9 Further research is needed 
to investigate possible biologic mechanisms for increased VTE risk, identify possible subgroups 
of individuals at increased risk. More broadly, resources and research are needed regarding 
prevention of and risk factor for chronic pain (e.g., obesity, poor fitness, injury) and to expand 
therapeutic approaches for effective pain management.  
6.4. Conclusions 
 In summary, we found that initiation of NSAIDs was associated with increased VTE risk 
compared to non-initiation, but the association was null or diminished when compared with 
acetaminophen initiation. Our findings do not corroborate the existence of a strong association 
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of NSAID use with VTE risk as has been suggested by authors of some previous 
pharmacoepidemiologic studies. Apparent risks of VTE associated with NSAID use in 
observational studies may be explained by confounding by indication. In our study of 
unmeasured confounding, BMI was difficult to predict and the magnitude of confounding by BMI 
in our analysis was modest for the comparisons we constructed. MI approaches showed 
potential for confounding control with internal validation data in most situations despite 
suboptimal prediction, but performance was poor for small VSs that lacked ample outcome data, 
and our observations are limited to the scenario and samples that we examined. The active 
comparator design reduced unmeasured confounding without the requirement of additional data 
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